| 1 |
Lin Y, Cai H. Biological functions and therapeutic potential of SHCBP1 in human cancer. Biomed Pharmacother 2023;160:114362. [PMID: 36739763 DOI: 10.1016/j.biopha.2023.114362] [Reference Citation Analysis]
|
| 2 |
Qiao L, Qin S, Weng N, Li B, Luo M, Zhang Z, Zhou L, Wang D, Huang C. Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma. Liver Int 2023;43:928-44. [PMID: 36776105 DOI: 10.1111/liv.15540] [Reference Citation Analysis]
|
| 3 |
Sun L, Gu M, Cai J, Yang W, Pan B, Wang B, Zhang C, Guo W. Combining γ-GT, PIVKA-II, and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy. Clin Exp Pharmacol Physiol 2023;50:287-97. [PMID: 36507841 DOI: 10.1111/1440-1681.13745] [Reference Citation Analysis]
|
| 4 |
Zhang X, Zhuge J, Liu J, Xia Z, Wang H, Gao Q, Jiang H, Qu Y, Fan L, Ma J, Tan C, Luo W, Luo Y. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1153423] [Reference Citation Analysis]
|
| 5 |
Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36932227 DOI: 10.1038/s41575-023-00754-7] [Reference Citation Analysis]
|
| 6 |
Huang L, Xu R, Li W, Lv L, Lin C, Yang X, Yao Y, Saw PE, Xu X. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. Acta Biomater 2023:S1742-7061(23)00147-2. [PMID: 36931417 DOI: 10.1016/j.actbio.2023.03.014] [Reference Citation Analysis]
|
| 7 |
Gao Y, Xiao J, Chen Z, Ma Y, Liu X, Yang D, Leo HL, Yu H, Kong J, Guo Q. Engineering orthotopic tumor spheroids with organ-specific vasculatures for local chemoembolization evaluation. Biomater Sci 2023;11:2115-28. [PMID: 36723179 DOI: 10.1039/d2bm01632j] [Reference Citation Analysis]
|
| 8 |
Girardi DM, Sousa LP, Miranda TA, Haum FNC, Pereira GCB, Pereira AAL. Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers 2023;15:1680. [DOI: 10.3390/cancers15061680] [Reference Citation Analysis]
|
| 9 |
D'Artista L, Moschopoulou AA, Barozzi I, Craig AJ, Seehawer M, Herrmann L, Minnich M, Kang TW, Rist E, Henning M, Klotz S, Heinzmann F, Harbig J, Sipos B, Longerich T, Eilers M, Dauch D, Zuber J, Wang XW, Zender L. MYC determines lineage commitment in kras driven primary liver cancer development. J Hepatol 2023:S0168-8278(23)00175-7. [PMID: 36906109 DOI: 10.1016/j.jhep.2023.02.039] [Reference Citation Analysis]
|
| 10 |
Xu J, Zhou Y, Dong K, Gong J, Xiong W, Wang X, Gu C, Lu XY, Huang DP, Shen XD, She XK, Zhao XC, Yu XJ, Zhang H. Gene variation profile and the potential correlation with clinical characteristics in HBV-associated HCC patients of Sichuan Han nationality in China. Asian J Surg 2023:S1015-9584(23)00229-4. [PMID: 36894454 DOI: 10.1016/j.asjsur.2023.02.056] [Reference Citation Analysis]
|
| 11 |
Tsumura S, Shimose S, Niizeki T, Kuboyama E, Iwamoto H, Tanaka M, Moriyama E, Shirono T, Takaki K, Noda Y, Nakano M, Inoue M, Tsustumi K, Kuromatsu R, Koga H, Higuchi K, Kawaguchi T. Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib. J Gastroenterol Hepatol 2023. [PMID: 36880677 DOI: 10.1111/jgh.16168] [Reference Citation Analysis]
|
| 12 |
Lee SK, Choi JY, Jung ES, Kwon JH, Jang JW, Bae SH, Yoon SK. An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. Int J Mol Sci 2023;24. [PMID: 36902432 DOI: 10.3390/ijms24055002] [Reference Citation Analysis]
|
| 13 |
Lu J, Wang H, Cao W, Chen D, He Z, Xu J. Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma. Hum Cell 2023;36:712-24. [PMID: 36520346 DOI: 10.1007/s13577-022-00845-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Merchant N, Alam A, Bhaskar L. The correlation between hepatocellular carcinoma susceptibility and XRCC1 polymorphisms Arg194Trp, Arg280His, and Arg399Gln – A meta-analysis. Human Gene 2023. [DOI: 10.1016/j.humgen.2023.201165] [Reference Citation Analysis]
|
| 15 |
Agarwal PD, Lucey MR, Said A, Kratz J. Immunotherapy for HCC: limitations in patients with NASH. Ann Hepatol 2023;28:100886. [PMID: 36925208 DOI: 10.1016/j.aohep.2022.100886] [Reference Citation Analysis]
|
| 16 |
Xie L, Liu M, Cai M, Huang W, Guo Y, Liang L, Cai W, Liu J, Liang W, Tan Y, Lai M, Lin L, Zhu K. Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma. Biomed Pharmacother 2023;159:114254. [PMID: 36669362 DOI: 10.1016/j.biopha.2023.114254] [Reference Citation Analysis]
|
| 17 |
Cao L, Wang Q, Hong J, Han Y, Zhang W, Zhong X, Che Y, Ma Y, Du K, Wu D, Pang T, Wu J, Liang K. MVI-TR: A Transformer-Based Deep Learning Model with Contrast-Enhanced CT for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36900327 DOI: 10.3390/cancers15051538] [Reference Citation Analysis]
|
| 18 |
Wang XH, Liu CJ, Wen HQ, Duan XH, Jiao YQ, Liu YJ, Chen MS, Zhu KS, Mao XH, Zhou QF. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clin Transl Med 2023;13:e1214. [PMID: 36855781 DOI: 10.1002/ctm2.1214] [Reference Citation Analysis]
|
| 19 |
Li YN, Shi X, Sun D, Han S, Zou Y, Wang L, Yang L, Li Y, Shi Y, Guo J, O'Driscoll CM. Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma. Int J Pharm 2023;:122791. [PMID: 36863541 DOI: 10.1016/j.ijpharm.2023.122791] [Reference Citation Analysis]
|
| 20 |
Lee AJ, Wu AG, Yew KC, Shelat VG. Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis. World J Gastrointest Surg 2023; 15(2): 273-286 [DOI: 10.4240/wjgs.v15.i2.273] [Reference Citation Analysis]
|
| 21 |
Chen Y, Xia S, Zhang L, Qin X, Zhu Z, Ma T, Lu S, Chen J, Shi X, Ren H. Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Is a Promising Signature to Predict Prognosis and Therapies for Hepatocellular Carcinoma (HCC). J Clin Med 2023;12. [PMID: 36902617 DOI: 10.3390/jcm12051830] [Reference Citation Analysis]
|
| 22 |
Zhou F, Kang Q, Ma J, Cai J, Chen Y, Qu K, Li F. Integrated analysis of RNA-seq in hepatocellular carcinoma reveals competing endogenous RNA network composed of circRNA, lncRNA, and mRNA. Medicine (Baltimore) 2023;102:e32915. [PMID: 36827016 DOI: 10.1097/MD.0000000000032915] [Reference Citation Analysis]
|
| 23 |
Liu Y, Fu L, Qu G, Peng S. Developing a signature based on necroptosis-related lncRNAs to predict the prognosis and immunotherapy response of hepatocellular carcinoma.. [DOI: 10.21203/rs.3.rs-2569265/v1] [Reference Citation Analysis]
|
| 24 |
Chen M, Li Z, Gu C, Zheng H, Chen Y, Cheng L. Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma. Cell Death Dis 2023;14:143. [PMID: 36805440 DOI: 10.1038/s41419-023-05675-6] [Reference Citation Analysis]
|
| 25 |
Liu X, Wang X, Luo Y, Wang M, Chen Z, Han X, Zhou S, Wang J, Kong J, Yu H, Wang X, Tang X, Guo Q. A 3D Tumor-Mimicking In Vitro Drug Release Model of Locoregional Chemoembolization Using Deep Learning-Based Quantitative Analyses. Adv Sci (Weinh) 2023;:e2206195. [PMID: 36793129 DOI: 10.1002/advs.202206195] [Reference Citation Analysis]
|
| 26 |
Solino GA, Ferreira RPCPC, D’albuquerque LAC, Farias AQ, Trindade LZ, Vasconcelos VFD, Pacheco MP. Atezolizumabe mais Bevacizumabe como Ponte para Transplante Hepático no Carcinoma Hepatocelular. BJT 2023;26. [DOI: 10.53855/bjt.v26i1.444_port] [Reference Citation Analysis]
|
| 27 |
Yang Z, Gao S, Wong CC, Liu W, Chen H, Shang H, Wu ZY, Xu L, Zhang X, Wong N, Kuang M, Yu J. TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Pathol 2023. [PMID: 36787097 DOI: 10.1002/path.6065] [Reference Citation Analysis]
|
| 28 |
Solino GA, Ferreira RPCPC, D’albuquerque LAC, Farias AQ, Trindade LZ, Vasconcelos VFD, Pacheco MP. Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma. BJT 2023;26. [DOI: 10.53855/bjt.v26i1.444_eng] [Reference Citation Analysis]
|
| 29 |
Shen J, Sun W, Liu J, Li J, Li Y, Gao Y. Metabolism-related signatures is correlated with poor prognosis and immune infiltration in hepatocellular carcinoma via multi-omics analysis and basic experiments. Front Oncol 2023;13:1130094. [PMID: 36860325 DOI: 10.3389/fonc.2023.1130094] [Reference Citation Analysis]
|
| 30 |
Lin Z, Li H, He C, Yang M, Chen H, Yang X, Zhuo J, Shen W, Hu Z, Pan L, Wei X, Lu D, Zheng S, Xu X. Metabolomic biomarkers for the diagnosis and post-transplant outcomes of AFP negative hepatocellular carcinoma. Front Oncol 2023;13:1072775. [PMID: 36845695 DOI: 10.3389/fonc.2023.1072775] [Reference Citation Analysis]
|
| 31 |
Cui S, Chen Y, Guo Y, Wang X, Chen D. Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration/ invasion by indirectly regulating SPRY2. PLoS One 2023;18:e0281536. [PMID: 36749775 DOI: 10.1371/journal.pone.0281536] [Reference Citation Analysis]
|
| 32 |
Gao B, Wang Y, Li C, Lu S. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma. Front Immunol 2023;14:1114717. [PMID: 36814910 DOI: 10.3389/fimmu.2023.1114717] [Reference Citation Analysis]
|
| 33 |
Wu S, Fan K, Yang Q, Chen Z, Hou Y, Zou Y, Cai W, Kang L. Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art. J Nanobiotechnology 2023;21:42. [PMID: 36747202 DOI: 10.1186/s12951-023-01804-7] [Reference Citation Analysis]
|
| 34 |
Wu H, Zhang Z, Han X, Zhang S, Zhang J, Han P, Zhang Y, Bai Y, Zhang Y. Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway. Oxid Med Cell Longev 2023;2023:5207431. [PMID: 36785788 DOI: 10.1155/2023/5207431] [Reference Citation Analysis]
|
| 35 |
Li D, Lei L, Wang J, Tang B, Wang J, Dong R, Shi W, Liu G, Zhao T, Wu Y, Zhang Y. Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma. Front Genet 2023;14:1075347. [PMID: 36816040 DOI: 10.3389/fgene.2023.1075347] [Reference Citation Analysis]
|
| 36 |
Wang R, Xu H, Chen W, Jin L, Ma Z, Wen L, Wang H, Cao K, Du X, Li M. Gadoxetic acid-enhanced MRI with a focus on LI-RADS v2018 imaging features predicts the prognosis after radiofrequency ablation in small hepatocellular carcinoma. Front Oncol 2023;13:975216. [PMID: 36816925 DOI: 10.3389/fonc.2023.975216] [Reference Citation Analysis]
|
| 37 |
Bian X, Zhang Y, Li N, Shi M, Chen X, Zhang H, Liu J, Wu J. Ultrasensitive quantification of trace amines based on N-phosphorylation labeling chip 2D LC-QQQ/MS. Journal of Pharmaceutical Analysis 2023. [DOI: 10.1016/j.jpha.2023.02.003] [Reference Citation Analysis]
|
| 38 |
An M, Wang W, Zhang J, Till BG, Zhao L, Huang H, Yang Y, Li T, Han L, Zhang X, Qin P, Wang Y, Zhang M, Cui H, Gao Q, Wang Z. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunol Immunother 2023;72:385-95. [PMID: 35907016 DOI: 10.1007/s00262-022-03254-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 39 |
Liu S, Huttad L, He G, He W, Liu C, Cai D, Chen H, Qiu J. Long noncoding RNA HULC regulates the NF-κB pathway and represents a promising prognostic biomarker in liver cancer. Cancer Med 2023;12:5124-36. [PMID: 36213936 DOI: 10.1002/cam4.5263] [Reference Citation Analysis]
|
| 40 |
Oura K, Morishita A, Hamaya S, Fujita K, Masaki T. The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36769116 DOI: 10.3390/ijms24032805] [Reference Citation Analysis]
|
| 41 |
Cheng HY, Ho CM, Hsiao CY, Ho MC, Wu YM, Lee PH, Hu RH. Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. HPB (Oxford) 2023;25:218-28. [PMID: 36376221 DOI: 10.1016/j.hpb.2022.10.010] [Reference Citation Analysis]
|
| 42 |
Yang C, Shao Y, Wang X, Wang J, Wang P, Huang C, Wang W, Wang J. The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36768989 DOI: 10.3390/ijms24032653] [Reference Citation Analysis]
|
| 43 |
Wang X, Li Y, Xiao Y, Huang X, Wu X, Zhao Z, Yang M, Kong L, Shi D, Chen X, Ouyang Y, Chen X, Lin C, Li J, Song L, Lin Y, Guan J. The phospholipid flippase ATP9A enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma. J Pathol 2023. [PMID: 36715683 DOI: 10.1002/path.6059] [Reference Citation Analysis]
|
| 44 |
Ishido S, Tsuchiya K, Kano Y, Yasui Y, Takaura K, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Tanaka S, Maeyashiki C, Tamaki N, Takahashi Y, Nakanishi H, Sakurai U, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765676 DOI: 10.3390/cancers15030719] [Reference Citation Analysis]
|
| 45 |
Zhang Q, Feng X, Zhang M, Sun W, Zhai Y, Qing S, Liu Y, Zhao H, Zhang Y, Ma Z, Sun J. Clinical Plasma Cells-related Genes to Aid Therapy in Colon Cancer.. [DOI: 10.21203/rs.3.rs-2483973/v1] [Reference Citation Analysis]
|
| 46 |
Laface C, Ranieri G, Maselli FM, Ambrogio F, Foti C, Ammendola M, Laterza M, Cazzato G, Memeo R, Mastrandrea G, Lioce M, Fedele P. Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765612 DOI: 10.3390/cancers15030654] [Reference Citation Analysis]
|
| 47 |
Yin X, Jiang K, Zhou Z, Yu H, Yan D, He X, Yan S. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer. Oxid Med Cell Longev 2023;2023:3878796. [PMID: 36713030 DOI: 10.1155/2023/3878796] [Reference Citation Analysis]
|
| 48 |
Gao B, Wang Y, Lu S. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Sci Rep 2023;13:1137. [PMID: 36670201 DOI: 10.1038/s41598-023-28436-z] [Reference Citation Analysis]
|
| 49 |
Wang XH, Duan WB, Liang W, Li H, Xie XY, Li SQ, Chen MS, Liang P, Mao XH, Zhou QF. Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort study. EClinicalMedicine 2023;56:101816. [PMID: 36703645 DOI: 10.1016/j.eclinm.2022.101816] [Reference Citation Analysis]
|
| 50 |
Ye M, Li X, Chen L, Mo S, Liu J, Huang T, Luo F, Zhang J. A High-Throughput Sequencing Data-Based Classifier Reveals the Metabolic Heterogeneity of Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765548 DOI: 10.3390/cancers15030592] [Reference Citation Analysis]
|
| 51 |
Luo L, Wang Z, Hu T, Feng Z, Zeng Q, Shu X, Wu A, Huang P, Cao Y, Tu Y, Li Z. Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. Biosci Rep 2023;43. [PMID: 36545914 DOI: 10.1042/BSR20222230] [Reference Citation Analysis]
|
| 52 |
Deng J, Liao Z, Gao J. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Curr Oncol 2023;30:1243-54. [PMID: 36661745 DOI: 10.3390/curroncol30010096] [Reference Citation Analysis]
|
| 53 |
Wu F, Tu C, Zhang K, Che H, Lin Q, Li Z, Zhou Q, Tang B, Yang Y, Chen M, Shao C. Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma. Biochem Biophys Res Commun 2023;640:173-82. [PMID: 36512849 DOI: 10.1016/j.bbrc.2022.11.084] [Reference Citation Analysis]
|
| 54 |
Shen C, Jiang X, Li M, Luo Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel) 2023;15. [PMID: 36672482 DOI: 10.3390/cancers15020533] [Reference Citation Analysis]
|
| 55 |
Wen K, Yang F, Hu L, Shi J, Mui S, Wang W, Liao H, Li H, Xiao Z, Yan Y. Analysis of the potential association between ferroptosis and immune in hepatocellular carcinoma and their relationship with prognosis. Front Oncol 2022;12:1031156. [PMID: 36776357 DOI: 10.3389/fonc.2022.1031156] [Reference Citation Analysis]
|
| 56 |
Zeng J, Wang J, Wu J, Deng R, Zhang L, Chen Q, Wang J, Jin X, Gui S, Xu Y, Lu X. A novel antimicrobial peptide M1-8 targets the lysosomal pathway to inhibit autolysosome formation and promote apoptosis in liver cancer cells. J Cell Mol Med 2023;27:340-52. [PMID: 36628597 DOI: 10.1111/jcmm.17644] [Reference Citation Analysis]
|
| 57 |
Cammarota A, Zanuso V, Manfredi GF, Murphy R, Pinato DJ, Rimassa L. Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing? Ther Adv Med Oncol 2023;15:17588359221148029. [PMID: 36643654 DOI: 10.1177/17588359221148029] [Reference Citation Analysis]
|
| 58 |
Fasano M, Pirozzi M, Famiglietti V, Facchini S, Caterino M, Caroprese M, Barillaro A, Di Giovanni I, Auriemma A, Ileana Sara Fattoruso S, Somma T, Solari D, Bocchetti M, Conson M, Pacelli R, Ciardiello F, Addeo R. Clinical activity of regorafenib in elderly patients with recurrent glioblastoma. Mol Clin Oncol 2023;18:9. [PMID: 36761386 DOI: 10.3892/mco.2023.2605] [Reference Citation Analysis]
|
| 59 |
Tang Y, Yuan F, Cao M, Li Y, Ren Y, Yang G, Zhong Z, He Z, Nan L, Deng M, Yao Z. CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance via PSIP1/c-Myc Axis Nuclear Translocation and Partially through Increasing EGFR Expression.. [DOI: 10.21203/rs.3.rs-2437109/v1] [Reference Citation Analysis]
|
| 60 |
Xie C, Gu A, Khan M, Yao X, Chen L, He J, Yuan F, Wang P, Yang Y, Wei Y, Tang F, Su H, Chen J, Li J, Cen B, Xu Z. Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening. Front Oncol 2022;12:1105454. [PMID: 36686807 DOI: 10.3389/fonc.2022.1105454] [Reference Citation Analysis]
|
| 61 |
Zhu Y, Wang Y, Hu M, Lu X, Sun G. Identification of oncogenes and tumor-suppressor genes with hepatocellular carcinoma: A comprehensive analysis based on TCGA and GEO datasets. Front Genet 2022;13:934883. [PMID: 36685860 DOI: 10.3389/fgene.2022.934883] [Reference Citation Analysis]
|
| 62 |
Yu Z, Wang K, Wan Z, Xie S, Lv Z. Popular deep learning algorithms for disease prediction: a review. Cluster Comput 2023;26:1231-51. [PMID: 36120180 DOI: 10.1007/s10586-022-03707-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 63 |
Liang L, Wang X, Huang S, Chen Y, Zhang P, Li L, Cui Y. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Front Immunol 2023;14:1046771. [PMID: 36936932 DOI: 10.3389/fimmu.2023.1046771] [Reference Citation Analysis]
|
| 64 |
Garufi C, Mancuso A. Hepatocellular Carcinoma Medical Therapy. Hepatocellular Carcinoma 2023. [DOI: 10.1007/978-3-031-09371-5_21] [Reference Citation Analysis]
|
| 65 |
Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol 2023;20:33-48. [PMID: 36307534 DOI: 10.1038/s41571-022-00699-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 66 |
Gao D, Xu X, Liu L, Liu L, Zhang X, Liang X, Cen L, Liu Q, Yuan X, Yu Z. Combination of Peglated-H1/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma. Appl Biochem Biotechnol 2023;195:505-18. [PMID: 36094649 DOI: 10.1007/s12010-022-04153-7] [Reference Citation Analysis]
|
| 67 |
Brandi G, Tovoli F, Tavolari S. Have We Found the "Holy Grail" That May Predict Response to Immunotherapy in Hepatocellular Carcinoma? Gastroenterology 2023;164:15-8. [PMID: 36334819 DOI: 10.1053/j.gastro.2022.10.030] [Reference Citation Analysis]
|
| 68 |
Chen X, Li J, Huang Y, Liang C. Drug Resistance in Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2022_110] [Reference Citation Analysis]
|
| 69 |
Jiang L, Li L, Liu Y, Lu L, Zhan M, Yuan S, Liu Y. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front Pharmacol 2023;14:1097277. [PMID: 36891274 DOI: 10.3389/fphar.2023.1097277] [Reference Citation Analysis]
|
| 70 |
Chen L, Zhang R, Lin Z, Tan Q, Huang Z, Liang B. Radiation therapy in the era of immune treatment for hepatocellular carcinoma. Front Immunol 2023;14:1100079. [PMID: 36742293 DOI: 10.3389/fimmu.2023.1100079] [Reference Citation Analysis]
|
| 71 |
Zhao Y, Zhang L, Hu Q, Zhu D, Xie Z. Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma. Comput Biol Med 2023;152:106348. [PMID: 36470143 DOI: 10.1016/j.compbiomed.2022.106348] [Reference Citation Analysis]
|
| 72 |
Xu Y, Yu X, Guo W, He Y. Emerging role of interaction between m6A and main ncRNAs in gastrointestinal (GI) cancers. Front Immunol 2023;14:1129298. [PMID: 36875073 DOI: 10.3389/fimmu.2023.1129298] [Reference Citation Analysis]
|
| 73 |
Gao Y, Gong Y, Liu Y, Xue Y, Zheng K, Guo Y, Hao L, Peng Q, Shi X. Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown. Acta Histochem 2023;125:151987. [PMID: 36473310 DOI: 10.1016/j.acthis.2022.151987] [Reference Citation Analysis]
|
| 74 |
Zhang B, Tao B, Li Y, Yi C, Lin Z, Ma Y, Han J, Shao W, Chen Z, Lin J, Chen J. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. Eur J Intern Med 2022:S0953-6205(22)00454-X. [PMID: 36588054 DOI: 10.1016/j.ejim.2022.12.025] [Reference Citation Analysis]
|
| 75 |
Chuanbing Z, Zhengle Z, Ruili D, Kongfan Z, Jing T. Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma. Biomolecules 2022;13. [PMID: 36671437 DOI: 10.3390/biom13010052] [Reference Citation Analysis]
|
| 76 |
Qiu R, Zeng Z. Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p. Can J Gastroenterol Hepatol 2022;2022:1206134. [PMID: 36594050 DOI: 10.1155/2022/1206134] [Reference Citation Analysis]
|
| 77 |
Tao H, Zhang Y, Li J, Liu J, Yuan T, Wang W, Liang H, Zhang E, Huang Z. Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma. Mol Ther Oncolytics 2023;28:88-103. [PMID: 36699616 DOI: 10.1016/j.omto.2022.12.005] [Reference Citation Analysis]
|
| 78 |
Volponi C, Gazzillo A, Bonavita E. The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network. Cancers (Basel) 2022;14. [PMID: 36551635 DOI: 10.3390/cancers14246151] [Reference Citation Analysis]
|
| 79 |
Cochrane Hepato-Biliary Group, Jingxin Yan, Manjun Deng, Ting Li, Yaxuan Wang, Jiaxin Wu, LuShun Zhang, Haining Fan. Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2022;2022:CD015389. [ DOI: 10.1002/14651858.CD015389] [Reference Citation Analysis]
|
| 80 |
Wen Z, He K, Zhan M, Li Y, Liu F, He X, Wei Y, Zhao W, Zhang Y, Xue Y, Xia Y, Wang F, Xia Z, Xin Y, Wu Y, Duan X, Xiao J, Shen F, Feng Y, Xiang G, Lu L. Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development. Front Oncol 2022;12:904633. [PMID: 36578923 DOI: 10.3389/fonc.2022.904633] [Reference Citation Analysis]
|
| 81 |
Sun KX, Cao SS, Shi FH, Guan Y, Tang M, Zhao MN, Jian YF, Cui B, Li ZY, Wang JW, Yu F, Ding Y. First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States. Therap Adv Gastroenterol 2022;15:17562848221140662. [PMID: 36518883 DOI: 10.1177/17562848221140662] [Reference Citation Analysis]
|
| 82 |
Guan J, Pan Y, Li H, Zhu Y, Gao Y, Wang J, Zhou Y, Guan Z, Yang Z. Activity and Tissue Distribution of Antisense Oligonucleotide CT102 Encapsulated with Cytidinyl/Cationic Lipid against Hepatocellular Carcinoma. Mol Pharm 2022;19:4552-64. [PMID: 35508302 DOI: 10.1021/acs.molpharmaceut.2c00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 83 |
Yuan XQ, Zhou N, Wang JP, Yang XZ, Wang S, Zhang CY, Li GC, Peng L. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma. Mol Ther 2022:S1525-0016(22)00671-2. [PMID: 36461633 DOI: 10.1016/j.ymthe.2022.11.013] [Reference Citation Analysis]
|
| 84 |
Chi Y, Gong Z, Xin H, Wang Z, Liu Z. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway. Cell Cycle 2022;21:2651-63. [PMID: 36003063 DOI: 10.1080/15384101.2022.2108275] [Reference Citation Analysis]
|
| 85 |
Fatima M, Karwasra R, Almalki WH, Sahebkar A, Kesharwani P. Galactose engineered nanocarriers: Hopes and hypes in cancer therapy. European Polymer Journal 2022. [DOI: 10.1016/j.eurpolymj.2022.111759] [Reference Citation Analysis]
|
| 86 |
Qin J, Chen X, Liu W, Chen J, Liu W, Xia Y, Li Z, Li M, Wang S, Yuan Q, Qiu Y, Wu Z, Fang M. Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. European Journal of Medicinal Chemistry 2022;244:114849. [DOI: 10.1016/j.ejmech.2022.114849] [Reference Citation Analysis]
|
| 87 |
Xia Y, Zhou L, Yang H, Yu C. Chemokine CCL5 immune subtypes of human liver cancer with prognostic significance. International Immunopharmacology 2022;113:109372. [DOI: 10.1016/j.intimp.2022.109372] [Reference Citation Analysis]
|
| 88 |
Dong H, Jian Y, Wang M, Liu F, Zhang Q, Peng Z, Cheng N, Zhang W. Hepatic artery intervention combined with immune-targeted therapy is superior to sequential therapy in BCLC-C hepatocellular carcinoma. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04386-3] [Reference Citation Analysis]
|
| 89 |
Wu T, Song Z, Huang H, Jakos T, Jiang H, Xie Y, Zhu J. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma. International Immunopharmacology 2022;113:109393. [DOI: 10.1016/j.intimp.2022.109393] [Reference Citation Analysis]
|
| 90 |
Yuan J, Liu Z, Wu Z, Yang J, Yang J. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. International Immunopharmacology 2022;113:109411. [DOI: 10.1016/j.intimp.2022.109411] [Reference Citation Analysis]
|
| 91 |
Wu H, Li Y, Shi G, Du S, Wang X, Ye W, Zhang Z, Chu Y, Ma S, Wang D, Li Y, Chen Z, Birnbaumer L, Wang Z, Yang Y. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology 2022;76:1602-16. [PMID: 34989013 DOI: 10.1002/hep.32316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 92 |
Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, Wang Y, Chan AW, Yan CW, Kwan KY, Wong YC, Li X, Zhou J, To KF, Zhu J, Lo CM, Cheng AS, Chan SL, Liu L, Song YQ, Man K, Chen Z. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut 2022:gutjnl-2022-327133. [PMID: 36450387 DOI: 10.1136/gutjnl-2022-327133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 93 |
Li X, Zhang Y, Ma W, Li J. An Elevated Neutrophil-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Liver Cancer after Interventional Treatments. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/6141317] [Reference Citation Analysis]
|
| 94 |
Rizzo A, Carloni R, Ricci AD, Cusmai A, Laforgia M, Calabrò C, Ungaro V, Oreste D, Sollitto M, Palmiotti G, Brandi G. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety 2022. [DOI: 10.1080/14740338.2023.2152793] [Reference Citation Analysis]
|
| 95 |
Liu LJ, Lv Z, Xue X, Xing ZY, Zhu F. Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy. Cancers (Basel) 2022;14. [PMID: 36497264 DOI: 10.3390/cancers14235781] [Reference Citation Analysis]
|
| 96 |
Hong Y, Zhang Y, Zhao H, Chen H, Yu Q, Cui H. The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1051306] [Reference Citation Analysis]
|
| 97 |
Dai X, Sun F, Deng K, Lin G, Yin W, Chen H, Yang D, Liu K, Zhang Y, Huang L. Mallotucin D, a Clerodane Diterpenoid from Croton crassifolius, Suppresses HepG2 Cell Growth via Inducing Autophagic Cell Death and Pyroptosis. Int J Mol Sci 2022;23. [PMID: 36430694 DOI: 10.3390/ijms232214217] [Reference Citation Analysis]
|
| 98 |
Wu W, Zhao L. Global research trends on immunotherapy in cancer: a visualization analysis.. [DOI: 10.21203/rs.3.rs-2204038/v1] [Reference Citation Analysis]
|
| 99 |
Ren H, Kang N, Yin S, Xu C, Qu T, Dai D. A Anoikis-Related Risk Model: Predicts Prognosis and Immunotherapy Response for Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2254618/v1] [Reference Citation Analysis]
|
| 100 |
Li SQ, Yang Y, Ye LS. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol 2022; 28(42): 6034-6044 [DOI: 10.3748/wjg.v28.i42.6034] [Reference Citation Analysis]
|
| 101 |
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 36369487 DOI: 10.1038/s41575-022-00704-9] [Reference Citation Analysis]
|
| 102 |
Jin Z, Song M, Wang J, Zhu W, Sun D, Liu H, Shi G. Integrative multiomics evaluation reveals the importance of pseudouridine synthases in hepatocellular carcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.944681] [Reference Citation Analysis]
|
| 103 |
Zhang Y, Gabere M, Tylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1042250] [Reference Citation Analysis]
|
| 104 |
Xie Y, Lin H, Wei W, Kong Y, Fang Q, Chen E, Liu J, Li M. LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia. Sci Rep 2022;12:18757. [PMID: 36335129 DOI: 10.1038/s41598-022-16972-z] [Reference Citation Analysis]
|
| 105 |
Wang YC, Tsai MC, Chen YS, Hsieh PM, Hung CM, Lin HY, Hsu YC, Yeh JH, Hsiao P, Su YC, Ma CH, Lee CY, Lin CC, Shu CW, Li YC, Tsai MH, Lin JY, Peng WH, Yu ML, Lin CW. NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. Hepatol Commun 2022;6:3563-77. [PMID: 36321403 DOI: 10.1002/hep4.2019] [Reference Citation Analysis]
|
| 106 |
Peng L, Yan Q, Chen Z, Hu Y, Sun Y, Miao Y, Wu Y, Yao Y, Tao L, Chen F, Li H, Xu T. Research progress on the role of cholesterol in hepatocellular carcinoma. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175410] [Reference Citation Analysis]
|
| 107 |
Li L, Liu HT, Teng YX, Deng ZJ, Zhang GL, Su JY, Ma L, Zhong JH. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. Expert Opin Investig Drugs 2022;31:1151-67. [PMID: 36437752 DOI: 10.1080/13543784.2022.2151891] [Reference Citation Analysis]
|
| 108 |
Testa U, Pelosi E, Castelli G. Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Rev Mol Diagn 2022;22:1009-35. [PMID: 36459631 DOI: 10.1080/14737159.2022.2154658] [Reference Citation Analysis]
|
| 109 |
Gu X, Zhang S, Yang X, Guan T, Hou Z, Cao M, Li H, Zhang T. Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma. BMC Gastroenterol 2022;22:441. [DOI: 10.1186/s12876-022-02542-0] [Reference Citation Analysis]
|
| 110 |
Yang C, Lee D, Zhang MS, Tse AP, Wei L, Bao MH, Wong BP, Chan CY, Yuen VW, Chen Y, Wong CC. Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. Adv Sci (Weinh) 2022;9:e2202104. [PMID: 36310121 DOI: 10.1002/advs.202202104] [Reference Citation Analysis]
|
| 111 |
Feng H, Zhuo Y, Zhang X, Li Y, Li Y, Duan X, Shi J, Xu C, Gao Y, Yu Z. Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. J Hepatocell Carcinoma 2022;9:1109-25. [PMID: 36320666 DOI: 10.2147/JHC.S381764] [Reference Citation Analysis]
|
| 112 |
Li Z, Cui Y, Duan Q, Zhang J, Shao D, Cao X, Gao Y, Wang S, Li J, Jones OD, Lei X, Wang L, Zhou X, Xu M, Ma J, Liu Y, Xu X. The Prognostic Significance of FKBP1A and Its Related Immune Infiltration in Liver Hepatocellular Carcinoma. IJMS 2022;23:12797. [DOI: 10.3390/ijms232112797] [Reference Citation Analysis]
|
| 113 |
Kuo H, Han M, Liao C, Lin Y, Wang C, Chen S, Chang T, Chen P, Lin S, Chen C, Chuang C, Wu I, Wu J, Hong T, Hsieh M, Lee Y, Wu H, Tsai H. Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceutics 2022;14:2263. [DOI: 10.3390/pharmaceutics14112263] [Reference Citation Analysis]
|
| 114 |
Gu X, Jiang C, Zhao J, Qiao Q, Wu M, Cai B. Identification of lipid metabolism-associated genes as prognostic biomarkers based on the immune microenvironment in hepatocellular carcinoma. Front Cell Dev Biol 2022;10:883059. [DOI: 10.3389/fcell.2022.883059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 115 |
Hu B, Zou T, Qin W, Shen X, Su Y, Li J, Chen Y, Zhang Z, Sun H, Zheng Y, Wang CQ, Wang Z, Li TE, Wang S, Zhu L, Wang X, Fu Y, Ren X, Dong Q, Qin LX. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Res 2022;82:3845-57. [PMID: 36066408 DOI: 10.1158/0008-5472.CAN-21-4140] [Reference Citation Analysis]
|
| 116 |
Zhang Q, Ma L, Zhou H, Zhou Y, Liu S, Li Q. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma. Front Oncol 2022;12:1040736. [DOI: 10.3389/fonc.2022.1040736] [Reference Citation Analysis]
|
| 117 |
Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020) 2022;3:e181. [PMID: 36254250 DOI: 10.1002/mco2.181] [Reference Citation Analysis]
|
| 118 |
Song L, Xu C, Zhang T, Chen S, Hu S, Cheng B, Tong H, Li X. Clinical neutrophil-associated genes as reliable predictors of hepatocellular carcinoma. Front Genet 2022;13:989779. [DOI: 10.3389/fgene.2022.989779] [Reference Citation Analysis]
|
| 119 |
Liu X, Sun B, Yao Y, Lai L, Wang X, Xiong J, Zhang X, Jiang J. Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma. Front Immunol 2022;13:996308. [PMID: 36275743 DOI: 10.3389/fimmu.2022.996308] [Reference Citation Analysis]
|
| 120 |
Cong T, Luo Y, Liu Y, Yang C, Yang H, Li Y, Li J, Li X. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma. Front Genet 2022;13:1000997. [DOI: 10.3389/fgene.2022.1000997] [Reference Citation Analysis]
|
| 121 |
Minami Y, Aoki T, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. Cancers (Basel) 2022;14. [PMID: 36230773 DOI: 10.3390/cancers14194850] [Reference Citation Analysis]
|
| 122 |
Wu G, Yang Y, Ye R, Yue H, Zhang H, Huang T, Liu M, Zheng Y, Wang Y, Zhou Y, Guo Q. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma. BMC Cancer 2022;22:1036. [PMID: 36195857 DOI: 10.1186/s12885-022-10049-w] [Reference Citation Analysis]
|
| 123 |
Li M, Zhang X, Wang M, Wang Y, Qian J, Xing X, Wang Z, You Y, Guo K, Chen J, Gao D, Zhao Y, Zhang L, Chen R, Cui J, Ren Z. Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma. Cancer Commun (Lond) 2022. [PMID: 36181398 DOI: 10.1002/cac2.12364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 124 |
de Castria TB, Khalil DN, Harding JJ, O'Reilly EM, Abou-Alfa GK. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncol 2022;18:3769-82. [PMID: 36399155 DOI: 10.2217/fon-2022-0652] [Reference Citation Analysis]
|
| 125 |
Yuan M, Liu L, Wang C, Zhang Y, Zhang J. The Complement System: A Potential Therapeutic Target in Liver Cancer. Life (Basel) 2022;12:1532. [PMID: 36294966 DOI: 10.3390/life12101532] [Reference Citation Analysis]
|
| 126 |
Gao Q, Fan L, Chen Y, Cai J. Identification of the hub and prognostic genes in liver hepatocellular carcinoma via bioinformatics analysis. Front Mol Biosci 2022;9:1000847. [DOI: 10.3389/fmolb.2022.1000847] [Reference Citation Analysis]
|
| 127 |
Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol 2022;12:980214. [DOI: 10.3389/fonc.2022.980214] [Reference Citation Analysis]
|
| 128 |
Xu L, Yang H, Yan M, Li W. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 36169759 DOI: 10.1007/s10238-022-00897-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 129 |
Zhao C, Zhang Z, Tao J. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients. Curr Oncol 2022;29:6992-7011. [PMID: 36290827 DOI: 10.3390/curroncol29100550] [Reference Citation Analysis]
|
| 130 |
Zhang C, Yang Y, Wang K, Chen M, Lu M, Hu C, Du X, Xing B, Liu X, Zhang J. The Systematic Analyses of RING Finger Gene Signature for Predicting the Prognosis of Patients with Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/2466006] [Reference Citation Analysis]
|
| 131 |
Li Z, Gao H, Zhang X, Liu Q, Chen G. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma: Prediction of stage I HCC prognosis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02496-3] [Reference Citation Analysis]
|
| 132 |
Cerrito L, Ainora ME, Mosoni C, Borriello R, Gasbarrini A, Zocco MA. Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. Cancers 2022;14:4647. [DOI: 10.3390/cancers14194647] [Reference Citation Analysis]
|
| 133 |
De Lorenzo S, Tovoli F, Trevisani F. Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers 2022;14:4616. [DOI: 10.3390/cancers14194616] [Reference Citation Analysis]
|
| 134 |
van Mourik H, Li M, Baumgartner S, Theys J, Shiri-sverdlov R. All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma. Biomedicines 2022;10:2351. [DOI: 10.3390/biomedicines10102351] [Reference Citation Analysis]
|
| 135 |
Khalid HR, Aamir M, Tabassum S, Alghamdi YS, Alzamami A, Ashfaq UA. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of Solanum surattense against Hepatocellular Carcinoma. Molecules 2022;27:6220. [DOI: 10.3390/molecules27196220] [Reference Citation Analysis]
|
| 136 |
Jost R, Al-Shatti N, Ghosn M, Bonnet B, Champiat S, Deschamps F, Gelli M, Boige V, Danlos FX, Susini S, Hollebecque A, Ammari S, Marabelle A, de Baere T, Tselikas L. Synergizing liver systemic treatments with interventional oncology: friend or foe? Br J Radiol 2022;95:20220548. [PMID: 36075034 DOI: 10.1259/bjr.20220548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 137 |
Mohapatra P, Chandrasekaran N. Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review. Biomed Pharmacother 2022;155:113713. [PMID: 36126453 DOI: 10.1016/j.biopha.2022.113713] [Reference Citation Analysis]
|
| 138 |
Zeng F, Dai H, Li X, Guo L, Jia N, Yang J, Huang D, Zeng H, Chen W, Zhang L, Qin G. Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study. Front Oncol 2022;12:916126. [DOI: 10.3389/fonc.2022.916126] [Reference Citation Analysis]
|
| 139 |
Zhang T, Wang Y, Xie M, Ji X, Luo X, Chen X, Zhang B, Liu D, Feng Y, Sun M, Huang W, Xia L. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. J Exp Clin Cancer Res 2022;41:275. [DOI: 10.1186/s13046-022-02475-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 140 |
Luan M, Zhao M, Wang H, Xu R, Cai J. Role of 5-methylcytosine in determining the prognosis, tumor microenvironment, and applicability of precision medicine in patients with hepatocellular carcinoma. Front Genet 2022;13:984033. [DOI: 10.3389/fgene.2022.984033] [Reference Citation Analysis]
|
| 141 |
Chen S, Liu P, Zhao L, Han P, Liu J, Yang H, Li J. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma. Front Immunol 2022;13:954653. [PMID: 36189204 DOI: 10.3389/fimmu.2022.954653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 142 |
Hong T, Su W, Pan Y, Tian C, Lei G. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Front Immunol 2022;13:951459. [DOI: 10.3389/fimmu.2022.951459] [Reference Citation Analysis]
|
| 143 |
Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol 2022; 14(9): 1622-1636 [DOI: 10.4251/wjgo.v14.i9.1622] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 144 |
Huang A, Du J, Liu Z, Zhang G, Abuduwaili W, Yan J, Sun J, Xu R, Liu T, Shen X, Dong L, Zhu J, Li Y. Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma. Nanomaterials 2022;12:3191. [DOI: 10.3390/nano12183191] [Reference Citation Analysis]
|
| 145 |
Jin Z, Wang M, Meng Y, Chen D, Xu Y, Jiang X, Xiong Z. Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma. J Healthc Eng 2022;2022:4694323. [PMID: 36147869 DOI: 10.1155/2022/4694323] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 146 |
Hu J, Yang L, Peng X, Mao M, Liu X, Song J, Li H, Chen F. METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma. Hum Cell 2022. [PMID: 36087219 DOI: 10.1007/s13577-022-00769-3] [Reference Citation Analysis]
|
| 147 |
Liu Z, Liu X, Shen H, Xu X, Zhao X, Fu R. Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy. Front Immunol 2022;13:978377. [DOI: 10.3389/fimmu.2022.978377] [Reference Citation Analysis]
|
| 148 |
Tong Q, Yi M, Kong P, Xu L, Huang W, Niu Y, Gan X, Zhan H, Tian R, Yan D. TRIM36 inhibits tumorigenesis through the Wnt/β-catenin pathway and promotes caspase-dependent apoptosis in hepatocellular carcinoma. Cancer Cell Int 2022;22:278. [PMID: 36068629 DOI: 10.1186/s12935-022-02692-x] [Reference Citation Analysis]
|
| 149 |
Mossenta M, Busato D, Dal Bo M, Macor P, Toffoli G. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Int J Mol Sci 2022;23:10038. [PMID: 36077433 DOI: 10.3390/ijms231710038] [Reference Citation Analysis]
|
| 150 |
Qu W, Ding Z, Qu X, Tang Z, Zhu G, Fu X, Zhang Z, Zhang X, Huang A, Tang M, Tian M, Jiang X, Huang R, Tao C, Fang Y, Gao J, Wu X, Zhou J, Fan J, Liu W, Shi Y. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open 2022;6. [DOI: 10.1093/bjsopen/zrac114] [Reference Citation Analysis]
|
| 151 |
Liu J, Tao H, Yuan T, Li J, Li J, Liang H, Huang Z, Zhang E. Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Front Immunol 2022;13:992611. [DOI: 10.3389/fimmu.2022.992611] [Reference Citation Analysis]
|
| 152 |
Chen J, Yao S, Sun Z, Wang Y, Yue J, Cui Y, Yu C, Xu H, Li L. The pattern of expression and prognostic value of key regulators for m7G RNA methylation in hepatocellular carcinoma. Front Genet 2022;13:894325. [DOI: 10.3389/fgene.2022.894325] [Reference Citation Analysis]
|
| 153 |
Sun R, Ma W, Ling M, Tang C, Zhong M, Dai J, Zhu M, Cai X, Li G, Xu Q, Tang L, Yu Z, Peng Z. pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors. J Control Release 2022;350:525-37. [PMID: 36055597 DOI: 10.1016/j.jconrel.2022.08.050] [Reference Citation Analysis]
|
| 154 |
Song D, An K, Zhai W, Feng L, Xu Y, Sun R, Wang Y, Yang Y, Kan Q, Tian X. NSUN2-mediated mRNA m5C Modification Regulates the Progression of Hepatocellular Carcinoma. Genomics, Proteomics & Bioinformatics 2022. [DOI: 10.1016/j.gpb.2022.09.007] [Reference Citation Analysis]
|
| 155 |
Elshami M, Hoehn R, Hue JJ, Rothermel L, Chavin KD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. HPB (Oxford) 2022;24:1482-91. [PMID: 35370098 DOI: 10.1016/j.hpb.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 156 |
Zhong K, Xu Y, Cheng Y, Wen Y, Cai L, He G, Huang H, Fu S, Zhong X, Zheng Y, Chen T, Huang M, Pan M. Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. Front Immunol 2022;13:999763. [DOI: 10.3389/fimmu.2022.999763] [Reference Citation Analysis]
|
| 157 |
Fan L, Xu L, Tian S, Zheng X. Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing. Front Endocrinol 2022;13:965445. [DOI: 10.3389/fendo.2022.965445] [Reference Citation Analysis]
|
| 158 |
Dai Y, Gao Y, Chen L, Liu J, Zeng C, Zhou J, Wu H. Predicting prognosis and immune responses in hepatocellular carcinoma based on N7-methylguanosine-related long noncoding RNAs. Front Genet 2022;13:930446. [DOI: 10.3389/fgene.2022.930446] [Reference Citation Analysis]
|
| 159 |
Alafnan A, Alamri A, Alanazi J, Hussain T. Farnesiferol C Exerts Antiproliferative Effects on Hepatocellular Carcinoma HepG2 Cells by Instigating ROS-Dependent Apoptotic Pathway. Pharmaceuticals (Basel) 2022;15. [PMID: 36145291 DOI: 10.3390/ph15091070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 160 |
Li A, Ye B, Lin F, Zhou P, Wang Y, Miao X, Jiang Y. Dissecting Novel Tumor Antigens and Immune Subtypes Guided mRNA Vaccine Development for HBV Related-Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-1962830/v1] [Reference Citation Analysis]
|
| 161 |
Wang D, Long G, Fang T, Zhou L. Splenic artery ligation ameliorates postoperation liver function in HCC who underwent hepatectomy.. [DOI: 10.21203/rs.3.rs-1947910/v1] [Reference Citation Analysis]
|
| 162 |
Muñoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA. Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Sci Rep 2022;12:14449. [PMID: 36002545 DOI: 10.1038/s41598-022-15948-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 163 |
Ma X, Wu S, Li B, Zhang Q, Zhang J, Liu W, Yan H, Bernards R, Qin W, Wang C. EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma. Cell Discov 2022;8:82. [PMID: 35999219 DOI: 10.1038/s41421-022-00425-y] [Reference Citation Analysis]
|
| 164 |
Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 2022. [PMID: 35989535 DOI: 10.1002/hep.32740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 165 |
Ning Y, Lin K, Liu X, Ding Y, Jiang X, Zhang Z, Xuan Y, Dong L, Liu L, Wang F, Zhao Q, Wang H, Fang J. NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02475-8] [Reference Citation Analysis]
|
| 166 |
Song B, Chi H, Peng G, Song Y, Cui Z, Zhu Y, Chen G, Wu J, Liu W, Dong C, Wang Y, Xu K, Yu Z, Song B. Characterization of coagulation-related gene signature to predict prognosis and tumor immune microenvironment in skin cutaneous melanoma. Front Oncol 2022;12:975255. [DOI: 10.3389/fonc.2022.975255] [Reference Citation Analysis]
|
| 167 |
Yang F, Zhao Y, Huang X, Zhang J, Zhang T, Sun Y. A Cell Differentiation Trajectory-Related Signature for Predicting the Prognosis of Lung Adenocarcinoma. Genetics Research 2022;2022:1-11. [DOI: 10.1155/2022/3483498] [Reference Citation Analysis]
|
| 168 |
Sun Y, Guan X, Zhang T, Li Y, Shi H, Chitakunye AT, Hong H, Zhang S, Zhu Q, Cai L. Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy. Med Oncol 2022;39:159. [PMID: 35972600 DOI: 10.1007/s12032-022-01767-z] [Reference Citation Analysis]
|
| 169 |
Le Y, Kong H, Gao X, Zhu J, Chen G. Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining. Computational and Mathematical Methods in Medicine 2022;2022:1-15. [DOI: 10.1155/2022/8371885] [Reference Citation Analysis]
|
| 170 |
Gongye X, Tian M, Xia P, Qu C, Chen Z, Wang J, Zhu Q, Li Z, Yuan Y. Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor. J Control Release 2022;350:11-25. [PMID: 35963466 DOI: 10.1016/j.jconrel.2022.08.010] [Reference Citation Analysis]
|
| 171 |
Liu J, Nie C. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma. Anticancer Drugs 2022. [PMID: 35946516 DOI: 10.1097/CAD.0000000000001329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 172 |
Liang Y, Zhang Z, Zhong D, Lai C, Dai Z, Zou H, Feng T, Shang J, Shi Y, Huang X. The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients. Front Oncol 2022;12:913731. [DOI: 10.3389/fonc.2022.913731] [Reference Citation Analysis]
|
| 173 |
Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, Zhou X, Li X, Zhou J. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol 2022;13:929141. [DOI: 10.3389/fimmu.2022.929141] [Reference Citation Analysis]
|
| 174 |
Gu Y, Chen B, Guo D, Pan L, Luo X, Tang J, Yang W, Zhang Y, Zhang L, Huang J, Duan R, Wang Z, Zhang J. Up-Regulation of RACGAP1 Promotes Progressions of Hepatocellular Carcinoma Regulated by GABPA via PI3K/AKT Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/3034150] [Reference Citation Analysis]
|
| 175 |
Wang K, Gu C, Yu G, Lin J, Wang Z, Lu Q, Xu Y, Zhao D, Jiang X, Mai W, Liu S, Yang H. Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression. Liver Research 2022. [DOI: 10.1016/j.livres.2022.08.003] [Reference Citation Analysis]
|
| 176 |
Li W, Pei Y, Wang Z, Liu J. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12:930868. [DOI: 10.3389/fonc.2022.930868] [Reference Citation Analysis]
|
| 177 |
Chen Y, Li H, Chen D, Jiang X, Wang W, Li D, Shan H. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression. Dig Dis Sci 2022;67:3806-16. [PMID: 34383201 DOI: 10.1007/s10620-021-07202-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 178 |
Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao H, Guo H, Sun S, Li M, Zhao D, Li X, Qi W, Zhang Y. Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chin Med 2022;17:90. [PMID: 35907976 DOI: 10.1186/s13020-022-00645-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Zhou J, Shao Q, Lu Y, Li Y, Xu Z, Zhou B, Chen Q, Li X, Xu X, Pan Y, Deng Z, Wang Y, Yu Y, Gu J. Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. Front Oncol 2022;12:960066. [DOI: 10.3389/fonc.2022.960066] [Reference Citation Analysis]
|
| 180 |
Liu L, Liu Z, Gao J, Liu X, Weng S, Guo C, Hu B, Wang Z, Zhang J, Shi J, Guo W, Zhang S. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma. Front Immunol 2022;13:964190. [DOI: 10.3389/fimmu.2022.964190] [Reference Citation Analysis]
|
| 181 |
Hu B, Gao J, Shi J, Zhang F, Shi C, Wen P, Wang Z, Guo W, Zhang S. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma. Front Immunol 2022;13:970117. [DOI: 10.3389/fimmu.2022.970117] [Reference Citation Analysis]
|
| 182 |
Li R, Okada H, Yamashita T, Nio K, Chen H, Li Y, Shimakami T, Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition. IJMS 2022;23:8305. [DOI: 10.3390/ijms23158305] [Reference Citation Analysis]
|
| 183 |
Li Y, Xu C, Sun B, Zhong F, Cao M, Yang L. Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA. Front Oncol 2022;12:913498. [DOI: 10.3389/fonc.2022.913498] [Reference Citation Analysis]
|
| 184 |
Wang W, Pan F, Lin X, Yuan J, Tao C, Wang R. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. Front Genet 2022;13:907331. [DOI: 10.3389/fgene.2022.907331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 185 |
Ilieva M, Dao J, Miller HE, Madsen JH, Bishop AJR, Kauppinen S, Uchida S. Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease. Noncoding RNA 2022;8. [PMID: 35893239 DOI: 10.3390/ncrna8040056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Ran R, Gong CY, Wang ZQ, Zhou WM, Zhang SB, Shi YQ, Ma CW, Zhang HH. Long non‑coding RNA PART1: dual role in cancer. Hum Cell 2022. [PMID: 35864416 DOI: 10.1007/s13577-022-00752-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 187 |
Ma X, Ma X, Zhu L, Zhao Y, Chen M, Li T, Lin Y, Ma D, Sun C, Han L. The E3 ubiquitin ligase MG53 inhibits hepatocellular carcinoma by targeting RAC1 signaling. Oncogenesis 2022;11:40. [PMID: 35858925 DOI: 10.1038/s41389-022-00414-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 188 |
Hu Y, Tang C, Zhu W, Ye H, Lin Y, Wang R, Zhou T, Wen S, Yang J, Fang C. Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy. Comput Biol Med 2022;148:105896. [PMID: 35868048 DOI: 10.1016/j.compbiomed.2022.105896] [Reference Citation Analysis]
|
| 189 |
Sun L, Yu S, Dong C, Wu Z, Huang H, Chen Z, Wu Z, Yin X. Comprehensive Analysis of Prognostic Value and Immune Infiltration of Ficolin Family Members in Hepatocellular Carcinoma. Front Genet 2022;13:913398. [DOI: 10.3389/fgene.2022.913398] [Reference Citation Analysis]
|
| 190 |
Li W, Li Y, Li P, Ma F, Liu M, Kong S, Xue H. miR-200a-3p- and miR-181-5p-Mediated HOXB5 Upregulation Promotes HCC Progression by Transcriptional Activation of EGFR. Front Oncol 2022;12:822760. [PMID: 35847904 DOI: 10.3389/fonc.2022.822760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 191 |
Lim JH, Park K, Choi KH, Kim CW, Lee JH, Weicker R, Pan C, Kim S, Park KC. Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. IJMS 2022;23:7971. [DOI: 10.3390/ijms23147971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 192 |
Liu P, Zhang X, Fu Q, Liu C, Luo Q, Yu P, Chen S, Zhang H, Qin T, Zhang Y. LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/9313680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 193 |
Jianxi W, Xiongfeng Z, Zehao Z, Zhen Z, Tianyi P, Ye L, Haosheng J, Zhixiang J, Huiling W. Indocyanine green fluorescence-guided laparoscopic hepatectomy versus conventional laparoscopic hepatectomy for hepatocellular carcinoma: A single-center propensity score matching study. Front Oncol 2022;12:930065. [DOI: 10.3389/fonc.2022.930065] [Reference Citation Analysis]
|
| 194 |
Jia J, Ga L, Liu Y, Yang Z, Wang Y, Guo X, Ma R, Liu R, Li T, Tang Z, Wang J. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Front Immunol 2022;13:923031. [DOI: 10.3389/fimmu.2022.923031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 195 |
Menshikov KV, Sultanbaev AV, Musin SI, Rakhmatullina IR, Menshikova IA, Abdeev RR, Sultanbaeva NI, Popova EV, Serebrennikov GA. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2022;12:139-150. [DOI: 10.24060/2076-3093-2022-12-2-139-150] [Reference Citation Analysis]
|
| 196 |
Wang W, Ye Y, Zhang X, Ye X, Liu C, Bao L. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:937979. [DOI: 10.3389/fmolb.2022.937979] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 197 |
Song B, Wu P, Liang Z, Wang J, Zheng Y, Wang Y, Chi H, Li Z, Song Y, Yin X, Yu Z, Song B. A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment. Front Genet 2022;13:917007. [DOI: 10.3389/fgene.2022.917007] [Reference Citation Analysis]
|
| 198 |
Zhu X, Zhang Y, Wu Y, Diao W, Deng G, Li Q, Wu C. HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters. Int J Genomics 2022;2022:9451557. [PMID: 35800617 DOI: 10.1155/2022/9451557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 199 |
Dar MA, Arafah A, Bhat KA, Khan A, Khan MS, Ali A, Ahmad SM, Rashid SM, Rehman MU. Multiomics technologies: role in disease biomarker discoveries and therapeutics. Brief Funct Genomics 2022:elac017. [PMID: 35809340 DOI: 10.1093/bfgp/elac017] [Reference Citation Analysis]
|
| 200 |
Guo Y, Yang J, Gao H, Tian X, Zhang X, Kan Q. Development and Verification of a Combined Immune- and Metabolism-Related Prognostic Signature for Hepatocellular Carcinoma. Front Immunol 2022;13:927635. [DOI: 10.3389/fimmu.2022.927635] [Reference Citation Analysis]
|
| 201 |
Wang H, Wu D, Gao C, Teng H, Zhao Y, He Z, Chen W, Zong Y, Du R. Seco-Lupane Triterpene Derivatives Induce Ferroptosis through GPX4/ACSL4 Axis and Target Cyclin D1 to Block the Cell Cycle. J Med Chem 2022. [PMID: 35801495 DOI: 10.1021/acs.jmedchem.2c00664] [Reference Citation Analysis]
|
| 202 |
Hu H, Huang W, Zhang H, Li J, Zhang Q, Miao YR, Hu FF, Gan L, Su Z, Yang X, Guo AY. A miR-9-5p/FOXO1/CPEB3 Feed-Forward Loop Drives the Progression of Hepatocellular Carcinoma. Cells 2022;11:2116. [PMID: 35805200 DOI: 10.3390/cells11132116] [Reference Citation Analysis]
|
| 203 |
Zhang Y, Wang X, Wang H, Jiang Y, Xu Z, Luo L. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:893107. [DOI: 10.3389/fonc.2022.893107] [Reference Citation Analysis]
|
| 204 |
Vishnoi K, Ke R, Viswakarma N, Srivastava P, Kumar S, Das S, Singh SK, Principe DR, Rana A, Rana B. Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma. Cell Death Dis 2022;13:581. [PMID: 35789155 DOI: 10.1038/s41419-022-05022-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 205 |
Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, Laurent A, Amaddeo G, Gentien D, Rapinat A, Regnault H, Charpy C, Nguyen CT, Tournigand C, Brustia R, Pawlotsky JM, Kather JN, Maiuri MC, Loménie N, Calderaro J. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 2022;77:116-27. [PMID: 35143898 DOI: 10.1016/j.jhep.2022.01.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 206 |
Wu C, Tian S, Guo Y, Yu C, Lei L, Zheng D, Xie H, Zheng J, Sun C. circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway. J Immunol Res 2022;2022:8649386. [PMID: 35769514 DOI: 10.1155/2022/8649386] [Reference Citation Analysis]
|
| 207 |
Deng X, Luo T, Zhang X, Li Y, Xie L, Jiang W, Liu L, Wang Z. Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. European Journal of Medicinal Chemistry 2022;237:114376. [DOI: 10.1016/j.ejmech.2022.114376] [Reference Citation Analysis]
|
| 208 |
Chen M, Wang H, Shi S, Zhang H, Xu S, Jiang Y. miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11. Archives of Biochemistry and Biophysics 2022. [DOI: 10.1016/j.abb.2022.109345] [Reference Citation Analysis]
|
| 209 |
Liu J, Liu B, Diao G, Zhang Z. Tissue factor promotes HCC carcinogenesis by inhibiting BCL2-dependent autophagy. Bulletin du Cancer 2022;109:795-804. [DOI: 10.1016/j.bulcan.2022.04.007] [Reference Citation Analysis]
|
| 210 |
Li R, Zhao W, Liang R, Jin C, Xiong H. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2022;9:917839. [DOI: 10.3389/fmolb.2022.917839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 211 |
Xia Z, Kong F, Wang K, Zhang X. Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. Front Pharmacol 2022;13:908079. [PMID: 35754499 DOI: 10.3389/fphar.2022.908079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 212 |
Adetutu Adisa R, Adegboyega Sulaimon L. Hepatocellular Carcinoma. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.105473] [Reference Citation Analysis]
|
| 213 |
Lai Y, Mi J, Feng Q. Fusobacterium nucleatum and Malignant Tumors of the Digestive Tract: A Mechanistic Overview. Bioengineering 2022;9:285. [DOI: 10.3390/bioengineering9070285] [Reference Citation Analysis]
|
| 214 |
Xia Y, Lin X, Cheng Y, Xu H, Zeng J, Xie W, Wang M, Sun Y. Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. Front Genet 2022;13:938796. [DOI: 10.3389/fgene.2022.938796] [Reference Citation Analysis]
|
| 215 |
Hou Y, Zhang R, Zong J, Wang W, Zhou M, Yan Z, Li T, Gan W, Lv S, Zeng Z, Yang M. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer. Front Immunol 2022;13:892512. [PMID: 35711437 DOI: 10.3389/fimmu.2022.892512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 216 |
Zhang M, Wang L, Liu W, Wang T, De Sanctis F, Zhu L, Zhang G, Cheng J, Cao Q, Zhou J, Tagliabue A, Bronte V, Yan D, Wan X, Yu G, Elkord E. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors. Journal of Immunology Research 2022;2022:1-21. [DOI: 10.1155/2022/2253436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 217 |
Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y, Xu X, Yao S, Guan Z, Tian J, Lu S, Xu B, Ma G. Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Front Oncol 2022;12:884372. [PMID: 35719917 DOI: 10.3389/fonc.2022.884372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 218 |
Khagazheeva MN, Dzhanyan IA, Breder VV, Laktionov KK. Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-9-157-162] [Reference Citation Analysis]
|
| 219 |
Zhang K, Su J, Chen D, Lin B, Wu Y, Wang Y, Lei J, Zheng R, Zhu B, Li Y. L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway. Mol Biol Rep 2022. [PMID: 35716289 DOI: 10.1007/s11033-022-07655-z] [Reference Citation Analysis]
|
| 220 |
Hernandez CA, Verzeroli C, Chicherova I, Farca-luna A, Tonon L, Bellaud P, Turlin B, Fautrel A, Macek-jilkova Z, Decaens T, Rebouissou S, Viari A, Zoulim F, Parent R. Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes.. [DOI: 10.1101/2022.06.14.495889] [Reference Citation Analysis]
|
| 221 |
Huang ZL, Xu B, Li TT, Xu YH, Huang XY, Huang XY. Integrative Analysis Identifies Cell-Type-Specific Genes Within Tumor Microenvironment as Prognostic Indicators in Hepatocellular Carcinoma. Front Oncol 2022;12:878923. [PMID: 35707353 DOI: 10.3389/fonc.2022.878923] [Reference Citation Analysis]
|
| 222 |
Munoz MA, Freeland J, O’donnell E, Langerman J, Darrow M, Thorpe S, Randall R, Plath K, Carraway K, Witte O, Graeber T, Carr-ascher JR. Transformation of Human Mesenchymal Stem Cells into High-Grade Sarcomas by YAP1 and K-RAS Reflects the Undifferentiated Pleomorphic Sarcoma-Myxofibrosarcoma Disease Spectrum.. [DOI: 10.1101/2022.06.13.495815] [Reference Citation Analysis]
|
| 223 |
Liao J, Yi Y, Yue X, Wu X, Zhu M, Chen Y, Peng S, Kuang M, Lin S, Peng Z. Methyltransferase 1 is required for nonhomologous end-joining repair and renders hepatocellular carcinoma resistant to radiotherapy. Hepatology 2022. [PMID: 35698894 DOI: 10.1002/hep.32615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 224 |
Wu MY, Wang CC, Chang YC, Yu CY, Sung WW, Chen CJ, Tsai MC. The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-κB Signaling. Medicina (Kaunas) 2022;58:798. [PMID: 35744061 DOI: 10.3390/medicina58060798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 225 |
Yang X, Xiao J, Jiang L, Ran L, Fan Y, Zhang M, Xu Y, Yao C, An B, Yang Y, Yang C, Tian G, Zhang G, Zhang Y. A Multifunctional Vanadium-Iron-Oxide Nanoparticle Eradicates Hepatocellular Carcinoma via Targeting Tumor and Endothelial Cells. ACS Appl Mater Interfaces 2022. [PMID: 35698257 DOI: 10.1021/acsami.2c03474] [Reference Citation Analysis]
|
| 226 |
Song D, An K, Zhai W, Feng L, Xu Y, Sun R, Wang Y, Yang Y, Kan Q, Tian X. NSUN2-mediated mRNA m5C Modification Regulates the Progression of Hepatocellular Carcinoma.. [DOI: 10.1101/2022.06.08.495406] [Reference Citation Analysis]
|
| 227 |
Sajid M, Liu L, Sun C. The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol 2022;13:887186. [PMID: 35669776 DOI: 10.3389/fimmu.2022.887186] [Reference Citation Analysis]
|
| 228 |
Dang W, Chen W, Ju E, Xu Y, Li K, Wang H, Wang K, Lv S, Shao D, Tao Y, Li M. 3D printed hydrogel scaffolds combining glutathione depletion-induced ferroptosis and photothermia-augmented chemodynamic therapy for efficiently inhibiting postoperative tumor recurrence. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01454-1] [Reference Citation Analysis]
|
| 229 |
Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 230 |
Jiang Z, Cheng L, Wu Z, Zhou L, Wang H, Hong Q, Wu Q, Long Y, Huang Y, Xu G, Yao Y, Tang Z, Zhang Z, Yang L, Luo W, Yang J, Gong L, Liu P, Chen X, Cui S, Zhang Q, Li Y, Li P. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Reports 2022;23. [DOI: 10.15252/embr.202154275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 231 |
Guang Y. Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma. Journal of Modern Nanotechnology 2022;2. [DOI: 10.53964/jmn.2022004] [Reference Citation Analysis]
|
| 232 |
Huang J, Kang W, Pan S, Yu C, Jie Z, Chen C, Ciccarone F. NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. Oxidative Medicine and Cellular Longevity 2022;2022:1-17. [DOI: 10.1155/2022/6891155] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 233 |
Sheng R, Zeng M, Jin K, Zhang Y, Wu D, Sun H. MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. Acad Radiol 2022;29:819-29. [PMID: 34649778 DOI: 10.1016/j.acra.2021.09.004] [Reference Citation Analysis]
|
| 234 |
Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022;12:e052294. [DOI: 10.1136/bmjopen-2021-052294] [Reference Citation Analysis]
|
| 235 |
Vishnoi K, Kumar S, Ke R, Rana A, Rana B. Dysregulation of immune checkpoint proteins in hepatocellular carcinoma: Impact on metabolic reprogramming. Current Opinion in Pharmacology 2022;64:102232. [DOI: 10.1016/j.coph.2022.102232] [Reference Citation Analysis]
|
| 236 |
Chen Q, Bao L, Huang Y, Lv L, Zhang G, Chen Y. Clinical significance and immunogenomic landscape analysis of glycolysis-associated prognostic model to guide clinical therapy in hepatocellular carcinoma. J Gastrointest Oncol 2022;13:1351-66. [PMID: 35837198 DOI: 10.21037/jgo-22-503] [Reference Citation Analysis]
|
| 237 |
Ye Q, Yang X, Zheng S, Mao X, Shao Y, Xuan Z, Huang P. Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma. Gene 2022;825:146437. [PMID: 35318110 DOI: 10.1016/j.gene.2022.146437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 238 |
Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. Int J Clin Oncol 2022. [PMID: 35633441 DOI: 10.1007/s10147-022-02174-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 239 |
Huang Y, Jiang L, Liu Y, Liu L, Wang J, Shi L. Long non-coding RNAs in virus-related cancers. Rev Med Virol 2022;:e2364. [PMID: 35607835 DOI: 10.1002/rmv.2364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 240 |
Liu P, Han B, Zhang Y, Wang X, Ahmad S. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/7102500] [Reference Citation Analysis]
|
| 241 |
Kim H, Jeong M, Na DH, Ryu SH, Jeong EI, Jung K, Kang J, Lee HJ, Sim T, Yu DY, Yu HC, Cho BH, Jung YK. AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis. Cell Death Dis 2022;13:469. [PMID: 35585049 DOI: 10.1038/s41419-022-04921-7] [Reference Citation Analysis]
|
| 242 |
Luo W, Guo S, Zhou Y, Zhao J, Wang M, Sang L, Chang B, Wang B. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Front Microbiol 2022;13:873160. [PMID: 35572649 DOI: 10.3389/fmicb.2022.873160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 243 |
Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
|
| 244 |
Wu Y, Xu X, Liu M, Qin X, Wu Q, Ding H, Zhao Q. DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis. Biochem Pharmacol 2022;:115093. [PMID: 35580648 DOI: 10.1016/j.bcp.2022.115093] [Reference Citation Analysis]
|
| 245 |
Zeng Z, Lei S, Wang J, Yang Y, Lan J, Tian Q, Chen T, Hao X. A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma. Bioengineered 2022;13:12193-210. [PMID: 35549979 DOI: 10.1080/21655979.2022.2073943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 246 |
Yu S, Wang H, Gao J, Liu L, Sun X, Wang Z, Wen P, Shi X, Shi J, Guo W, Zhang S. Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer. Front Genet 2022;13:863536. [DOI: 10.3389/fgene.2022.863536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 247 |
Machida K, Tahara SM. Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers (Basel) 2022;14. [PMID: 35625986 DOI: 10.3390/cancers14102381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 248 |
Wu T, Zheng X, Yang M, Zhao A, Xiang H, Chen T, Jia W, Ji G. Serum Amino Acid Profiles Predict the Development of Hepatocellular Carcinoma in Patients with Chronic HBV Infection. ACS Omega 2022;7:15795-808. [PMID: 35571782 DOI: 10.1021/acsomega.2c00885] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 249 |
Mínguez B, Lledó-Navarro JL. Foreword. Clin Drug Investig 2022. [PMID: 35532834 DOI: 10.1007/s40261-022-01148-4] [Reference Citation Analysis]
|
| 250 |
Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
|
| 251 |
Darwish NM, Elshaer MMA, Almutairi SM, Chen TW, Mohamed MO, Ghaly WBA, Rasheed RA. Omega-3 Polyunsaturated Fatty Acids Provoke Apoptosis in Hepatocellular Carcinoma through Knocking Down the STAT3 Activated Signaling Pathway: In Vivo and In Vitro Study. Molecules 2022;27:3032. [PMID: 35566382 DOI: 10.3390/molecules27093032] [Reference Citation Analysis]
|
| 252 |
Liu Y, Song J, Zhang H, Liao Z, Liu F, Su C, Wang W, Han M, Zhang L, Zhu H, Zhang Z, Liang H, Zhang L, Zhang B, Chen X. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. J Exp Clin Cancer Res 2022;41:164. [PMID: 35509064 DOI: 10.1186/s13046-022-02378-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 253 |
Li Z, Bu J, Zhu X, Zhou H, Ren K, Chu PK, Li L, Hu X, Ding X. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. Biomaterials Advances 2022;136:212761. [DOI: 10.1016/j.bioadv.2022.212761] [Reference Citation Analysis]
|
| 254 |
El-Demiry SM, El-Yamany M, El-Gendy SM, Salem HA, Saber MM. Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line. Life Sci 2022;301:120594. [PMID: 35500680 DOI: 10.1016/j.lfs.2022.120594] [Reference Citation Analysis]
|
| 255 |
Zhang G, Fan W, Wang H, Wen J, Tan J, Xue M, Li J. Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:844013. [DOI: 10.3389/fcell.2022.844013] [Reference Citation Analysis]
|
| 256 |
Zhao M, Duan X, Han X, Wang J, Han G, Mi L, Shi J, Li N, Yin X, Hou J, Yin F. Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells. Front Oncol 2022;12:854096. [PMID: 35463384 DOI: 10.3389/fonc.2022.854096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 257 |
Liao S, Wang K, Zhang L, Shi G, Wang Z, Chen Z, Zhu P, He Q. PRC1 and RACGAP1 are Diagnostic Biomarkers of Early HCC and PRC1 Drives Self-Renewal of Liver Cancer Stem Cells. Front Cell Dev Biol 2022;10:864051. [PMID: 35445033 DOI: 10.3389/fcell.2022.864051] [Reference Citation Analysis]
|
| 258 |
Hamaguchi K, Miyanishi K, Osuga T, Tanaka S, Ito R, Sakamoto H, Kubo T, Ohnuma H, Murase K, Takada K, Nagayama M, Kimura Y, Mizuguchi T, Takemasa I, Kato J. Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers 2022;14:2066. [DOI: 10.3390/cancers14092066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 259 |
Han Y, Jiang W, Wang Y, Zhao M, Li Y, Ren L. Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma. BMC Cancer 2022;22:431. [PMID: 35443674 DOI: 10.1186/s12885-022-09530-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 260 |
Weijia W, lei Z. Global research trends on immunotherapy in cancer: a visualization analysis (Preprint).. [DOI: 10.2196/preprints.38840] [Reference Citation Analysis]
|
| 261 |
Yang F, Deng K, Zheng H, Liu Z, Zheng Y. Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Ann Hepatol 2022;27:100677. [PMID: 35093601 DOI: 10.1016/j.aohep.2022.100677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 262 |
Brancolini C, Gagliano T, Minisini M. HDACs and the epigenetic plasticity of cancer cells: Target the complexity. Pharmacol Ther 2022;238:108190. [PMID: 35430294 DOI: 10.1016/j.pharmthera.2022.108190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 263 |
Park HJ, Choi G, Ha S, Kim Y, Choi M, Kim M, Islam MK, Chang Y, Kwon T, Kim D, Jang E, Kim TH, Chang SJ, Kim Y. MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases. Cancers 2022;14:1994. [DOI: 10.3390/cancers14081994] [Reference Citation Analysis]
|
| 264 |
Park H, Park H, Baek J, Moon H, Ro SW. Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Biology 2022;11:585. [DOI: 10.3390/biology11040585] [Reference Citation Analysis]
|
| 265 |
Zhou S, Xu J, Wang D, Wang Y, Meng L, Cao S. Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/5224434] [Reference Citation Analysis]
|
| 266 |
Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L, Guan X, Wang X, Lin B, Tian R, Chen K, Zhang X, Yang Z, Ji F, Huang Y, Wei W, Gong W, Ren J, Wang JM, Guo M, Huang J. CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma. Front Oncol 2022;12:831268. [DOI: 10.3389/fonc.2022.831268] [Reference Citation Analysis]
|
| 267 |
He W, Hu Y, Chen D, Li Y, Ye D, Zhao Q, Lin L, Shi X, Lu L, Yin Z, He X, Gao Y, Wu Y. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2+ γδ T cell can be a promising complement. Clin Transl Med 2022;12:e800. [PMID: 35390227 DOI: 10.1002/ctm2.800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 268 |
Zhong X, Yu X, Chang H. Exploration of a Novel Prognostic Nomogram and Diagnostic Biomarkers Based on the Activity Variations of Hallmark Gene Sets in Hepatocellular Carcinoma. Front Oncol 2022;12:830362. [PMID: 35359370 DOI: 10.3389/fonc.2022.830362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 269 |
Su Z, Luo L, Wu X, Wei B, Wang L, Liu F, Cai B. Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics. Immunol Res 2022. [PMID: 35364781 DOI: 10.1007/s12026-022-09271-2] [Reference Citation Analysis]
|
| 270 |
Wang H, He X, Fang D, Wang X, Guan J, Shi ZW, Chen X. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. Clin Res Hepatol Gastroenterol 2022;46:101853. [PMID: 34923183 DOI: 10.1016/j.clinre.2021.101853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 271 |
Guo Y, Yang J, Ren K, Tian X, Gao H, Tian X, Zhang X, Kan Q. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma. Front Immunol 2022;13:861525. [PMID: 35355983 DOI: 10.3389/fimmu.2022.861525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 272 |
Chen J, Jiang S, Shao H, Li B, Ji T, Staiculescu D, He J, Zhao J, Cai L, Liang X, Xu J, Cai X. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway. Sci China Life Sci 2022. [PMID: 35380342 DOI: 10.1007/s11427-021-2067-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 273 |
Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3:386-401. [PMID: 35484418 DOI: 10.1038/s43018-022-00357-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 274 |
Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y, Liu X. Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency. Adv Sci (Weinh) 2022;9:e2105631. [PMID: 35142445 DOI: 10.1002/advs.202105631] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 275 |
Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol 2022;16:333-9. [PMID: 35403533 DOI: 10.1080/17474124.2022.2064273] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 276 |
Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z, Huang X, Liu H, Hou J, Zhang X, Zhu W. Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:813275. [DOI: 10.3389/fonc.2022.813275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 277 |
Lai X, Wu Y, Hong G, Li J, Luo Q, Yuan J, Dai G, Liu S, Feng H, Wang F. A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9117205] [Reference Citation Analysis]
|
| 278 |
Yang S, Zhang J, Xu Y, Wang J, Zhao H, Lei J, Zhou Y, Chen Y, Wu L, Zhou M, Zheng L, Ji X, Li Y. OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunol Immunother 2022. [PMID: 35353239 DOI: 10.1007/s00262-022-03188-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 279 |
Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers (Basel) 2022;14. [PMID: 35406518 DOI: 10.3390/cancers14071747] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 280 |
Liu ZK, Wu KF, Zhang RY, Kong LM, Shang RZ, Lv JJ, Li C, Lu M, Yong YL, Zhang C, Zheng NS, Li YH, Chen ZN, Bian H, Wei D. Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2022;12:794034. [PMID: 35311105 DOI: 10.3389/fonc.2022.794034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 281 |
Akuta N, Kawamura Y, Suzuki F, Kobayashi M, Arase Y, Saitoh S, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Ikeda K, Kumada H. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. Hepatol Int. [DOI: 10.1007/s12072-022-10313-y] [Reference Citation Analysis]
|
| 282 |
Zhou L, Wang M, Guo H, Hou J, Zhang Y, Li M, Wu X, Chen X, Wang L. Integrated Analysis Highlights the Immunosuppressive Role of TREM2+ Macrophages in Hepatocellular Carcinoma. Front Immunol 2022;13:848367. [DOI: 10.3389/fimmu.2022.848367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 283 |
Coto-Llerena M, Benjak A, Gallon J, Meier MA, Boldanova T, Terracciano LM, Ng CKY, Piscuoglio S. Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma. JCO Precis Oncol 2022;6:e2100335. [PMID: 35263170 DOI: 10.1200/PO.21.00335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 284 |
Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 285 |
Zhang K, Barry AE, Lamm R, Patel K, Schafer M, Dang H. The role of RNA binding proteins in hepatocellular carcinoma. Adv Drug Deliv Rev 2022;182:114114. [PMID: 35063534 DOI: 10.1016/j.addr.2022.114114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 286 |
Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022;19:151-72. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Cited by in Crossref: 206] [Cited by in F6Publishing: 201] [Article Influence: 206.0] [Reference Citation Analysis]
|
| 287 |
Lewis S, Cedillo MA, Lee KM, Bane O, Hectors S, Ma W, Wang P, Stocker D, Morris DV, Pinato D, Sung M, Marron T, Schwartz M, Taouli B. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdom Radiol (NY) 2022;47:969-80. [PMID: 34964909 DOI: 10.1007/s00261-021-03386-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 288 |
Liu T, Yu J, Ge C, Zhao F, Chen J, Miao C, Jin W, Zhou Q, Geng Q, Lin H, Tian H, Chen T, Xie H, Cui Y, Yao M, Xiao X, Li J, Li H. Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215642] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 289 |
Zhang Y, Gabere M, Taylor M, Simoes CC, Dumbauld C, Barro O, Chamcheu JC, Post SR, Kelly TJ, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy.. [DOI: 10.1101/2022.02.25.481685] [Reference Citation Analysis]
|
| 290 |
Wei J, Niu M, Yabo O, Zhou Y, Ma X, Yang X, Jiang H, Hui H, Cao H, Duan B, Li H, Ding D, Tian J. Advances in artificial intelligence techniques drive the application of radiomics in the clinical research of hepatocellular carcinoma. iLIVER 2022;1:49-54. [DOI: 10.1016/j.iliver.2022.02.005] [Reference Citation Analysis]
|
| 291 |
Xu W, Cheng Y, Guo Y, Yao W, Qian H. Targeting tumor associated macrophages in hepatocellular carcinoma. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.114990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 292 |
Liu S, He L, Bannister OB, Schnegelberger RD, Tao J, Althouse AD, Schopfer FJ, Wahlang B, Cave MC, Monga SP, Zhang X, Arteel GE, Beier JI. Western diet unmasks transient low-level vinyl chloride exposure-induced tumorigenesis; potential role of the (epi-)transcriptome.. [DOI: 10.1101/2022.02.24.481808] [Reference Citation Analysis]
|
| 293 |
Shu Y, He L, Gao M, Xiao F, Yang J, Wang S, Wei H, Zhang F, Wei H. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma. Front Immunol 2021;12:780509. [PMID: 35069551 DOI: 10.3389/fimmu.2021.780509] [Reference Citation Analysis]
|
| 294 |
Liu W, Pan Y, Zhu H, Zhou Y, Zhang H, Liu L, Liu Q, Ji G. CircRNA_0008194 functions as a ceRNA to promote invasion of hepatocellular carcinoma via inhibiting miR-190a/AHNAK signaling pathway. J Clin Lab Anal 2022;:e24286. [PMID: 35199873 DOI: 10.1002/jcla.24286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 295 |
Jin Z, Sun D, Song M, Zhu W, Liu H, Wang J, Shi G, Wang F. Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/5758601] [Reference Citation Analysis]
|
| 296 |
Yan H, Wang X, Liu X, Wang P, Yu L, Zhou D, Yang Z. The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model. BMC Cancer 2022;22:185. [PMID: 35180841 DOI: 10.1186/s12885-022-09293-x] [Reference Citation Analysis]
|
| 297 |
Zhang Y, Zhang Y, Shi X, Li J, Wang L, Xie C, Wang Y. Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. Front Oncol 2022;12:836333. [DOI: 10.3389/fonc.2022.836333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 298 |
Xin Z, Li J, Zhang H, Zhou Y, Song J, Chen P, Bai L, Chen H, Zhou J, Chen J, Ying B. Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. Front Oncol 2022;12:783109. [PMID: 35155229 DOI: 10.3389/fonc.2022.783109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 299 |
Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis 2022;13:146. [PMID: 35165269 DOI: 10.1038/s41419-022-04583-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 300 |
Gungor MZ, Uysal M, Senturk S. The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. Cancers (Basel) 2022;14:940. [PMID: 35205692 DOI: 10.3390/cancers14040940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 301 |
Shi L, Cao J, Lei X, Shi Y, Wu L. Multi-omics data identified TP53 and LRP1B as key regulatory gene related to immune phenotypes via EPCAM in HCC. Cancer Med 2022. [PMID: 35150083 DOI: 10.1002/cam4.4594] [Reference Citation Analysis]
|
| 302 |
Hsu CH, Huang YH, Lin SM, Hsu C. AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer 2022;11:94-112. [PMID: 35634427 DOI: 10.1159/000520501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 303 |
Yan X, Zheng W, Chen SP, Zhang ZY, Du LX. Successful conversion therapy and radical resection for huge Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma: A case report. Shijie Huaren Xiaohua Zazhi 2022; 30(3): 164-168 [DOI: 10.11569/wcjd.v30.i3.164] [Reference Citation Analysis]
|
| 304 |
Deng M, Sun S, Zhao R, Guan R, Zhang Z, Li S, Wei W, Guo R. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. Mol Med 2022;28. [DOI: 10.1186/s10020-022-00445-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 305 |
Zhao C, Wu X, Chen J, Qian G. The therapeutic effect of IL-21 combined with IFN-γ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma. Journal of Advanced Research 2022;36:89-99. [DOI: 10.1016/j.jare.2021.05.010] [Reference Citation Analysis]
|
| 306 |
Xu X, Jiang W, Han P, Zhang J, Tong L, Sun X. MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met. JHC 2022;Volume 9:113-26. [DOI: 10.2147/jhc.s349369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 307 |
Carr BI, Guerra V, Donghia R, Ince V, Akbulut S, Ersan V, Usta S, Isik B, Samdanci E, Yilmaz S. Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2022;26:333-40. [PMID: 34506030 DOI: 10.1007/s11605-021-05126-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 308 |
Tian H, Chen Y, Zhang R, Liu J. The Role of COL22A1 in the Pathophysiology of Hepatocellular Carcinoma: Evidence from Bioinformatics Exploration. CMAR 2022;Volume 14:739-50. [DOI: 10.2147/cmar.s349991] [Reference Citation Analysis]
|
| 309 |
Takuma K, Fujihara S, Fujita K, Iwama H, Nakahara M, Oura K, Tadokoro T, Mimura S, Tani J, Shi T, Morishita A, Kobara H, Himoto T, Masaki T. Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. Int J Mol Sci 2022;23:1667. [PMID: 35163589 DOI: 10.3390/ijms23031667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 310 |
Tang Z, Yang Y, Chen W, Li E, Liang T. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med 2022;20:49. [PMID: 35093119 DOI: 10.1186/s12967-022-03249-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 311 |
Ouyang X, Lv L, Zhao Y, Zhang F, Hu Q, Li Z, Zhu D, Li L. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma. Front Oncol 2021;11:801506. [PMID: 35087760 DOI: 10.3389/fonc.2021.801506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 312 |
Chen X, Chi H, Zhao X, Pan R, Wei Y, Han Y, Granito A. Role of Exosomes in Immune Microenvironment of Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/2521025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 313 |
Ding L, Zhang P, Huang X, Yang K, Liu X, Yu Z. Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy. Front Pharmacol 2021;12:809125. [PMID: 35082681 DOI: 10.3389/fphar.2021.809125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 314 |
Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 315 |
Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 316 |
Krstic J, Reinisch I, Schindlmaier K, Galhuber M, Riahi Z, Berger N, Kupper N, Moyschewitz E, Auer M, Michenthaler H, Nössing C, Depaoli MR, Ramadani-muja J, Usluer S, Stryeck S, Pichler M, Rinner B, Deutsch AJA, Reinisch A, Madl T, Chiozzi RZ, Heck AJR, Huch M, Malli R, Prokesch A. Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Sci Adv 2022;8:eabh2635. [DOI: 10.1126/sciadv.abh2635] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 317 |
Kong H, Sun J, Zhang W, Zhang H, Li H. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered 2022;13:3108-21. [PMID: 35037556 DOI: 10.1080/21655979.2022.2025701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 318 |
Aoki T, Nishida N, Kudo M. Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma. Cancers 2022;14:444. [DOI: 10.3390/cancers14020444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 319 |
Zhang X, Zhang H, Liao Z, Zhang J, Liang H, Wang W, Yu J, Dong K. SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma. Cancer Cell Int 2022;22:24. [PMID: 35033067 DOI: 10.1186/s12935-022-02446-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 320 |
Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 321 |
Dong ZB, Wu HM, He YC, Huang ZT, Weng YH, Li H, Liang C, Yu WM, Chen W. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1. Cell Death Dis 2022;13:35. [PMID: 35013144 DOI: 10.1038/s41419-021-04491-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 322 |
Shi L, Wang F, Zhang Y, Yang Y, Qu Z, Sun D. Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2. Comput Math Methods Med 2021;2021:4439505. [PMID: 34992672 DOI: 10.1155/2021/4439505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 323 |
Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 2022;14:1. [PMID: 34986867 DOI: 10.1186/s13073-021-00995-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 324 |
Breder VV, Abdurakhmanov DT, Petkau VV, Balakhnin PV, Volkonsky MV, Grechukhina KS, Zafirova M, Mikerov IA, Pokataev IA, Khasanova A. Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib. Malignant Tumours 2022;11:45-52. [DOI: 10.18027/2224-5057-2021-11-3-45-52] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 325 |
Wen K, Yan Y, Shi J, Hu L, Wang W, Liao H, Li H, Zhu Y, Mao K, Xiao Z. Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:809672. [PMID: 34977159 DOI: 10.3389/fmolb.2021.809672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 326 |
Shen LJ, Sun HW, Chai YY, Jiang QY, Zhang J, Li WM, Xin SJ. The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. Front Oncol 2021;11:804412. [PMID: 34976842 DOI: 10.3389/fonc.2021.804412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 327 |
Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 328 |
Xu P, Luo A, Xiong C, Ren H, Yan L, Luo Q. SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway. Cancer Cell Int 2022;22:1. [PMID: 34980127 DOI: 10.1186/s12935-021-02402-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 329 |
Jia W, Han Y, Mao X, Xu W, Zhang Y. Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Adv 2022;12:31068-31082. [DOI: 10.1039/d2ra05127c] [Reference Citation Analysis]
|
| 330 |
Liu L, Liu Z, Meng L, Li L, Gao J, Yu S, Hu B, Yang H, Guo W, Zhang S. An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma. Front Mol Biosci 2021;8:766609. [PMID: 34970594 DOI: 10.3389/fmolb.2021.766609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 331 |
Acher AW, Rahnemai-azar AA, Weber SM, Pawlik TM. Surgical Approach to Pancreas, Liver, Biliary Physiologic Impairment. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_5] [Reference Citation Analysis]
|
| 332 |
Carabias P, Espelt MV, Bacigalupo ML, Rojas P, Sarrias L, Rubin A, Saffioti NA, Elola MT, Rossi JP, Wolfenstein-todel C, Rabinovich GA, Troncoso MF. Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. Cell Death Dis 2022;13:79. [DOI: 10.1038/s41419-022-04520-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 333 |
Buqué A, Montrose DC, Galluzzi L. Emergent impact of lifestyle on tumor progression and response to therapy. International Review of Cell and Molecular Biology 2022. [DOI: 10.1016/s1937-6448(22)00132-0] [Reference Citation Analysis]
|
| 334 |
Rela M, Quintero J, Kasahara M, Muiesan P, Hernández-Oliveros F, Rajalingam R, Shankar S, Sayed BA, di Sabato D, Rammohan A, Fung J, Bilbao I. Nonhepatic Cancer in the Pediatric Liver Transplant Population: Guidelines From the ILTS-SETH Consensus Conference. Transplantation 2022;106:e46-51. [PMID: 34905761 DOI: 10.1097/TP.0000000000003996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 335 |
Li L, Selaru FM. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.011] [Reference Citation Analysis]
|
| 336 |
Tian S, Hu Y, Yang C, Yu J, Liu J, Xuan G, Liu Y, Sun K, Zhang M, Ma S, Shang Y, Zhou X, Han Y; State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an 710032, China, Department of Radiation Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China, Department of Gastroenterology, The Air Force Hospital from Eastern Theater of PLA, Nanjing 210002, China. . MBE 2022;19:4719-36. [DOI: 10.3934/mbe.2022220] [Reference Citation Analysis]
|
| 337 |
Patil K, Dermime S, Uddin S. Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00016-1] [Reference Citation Analysis]
|
| 338 |
Cheng W, Zhang Y, Liu M. Identification of Subtypes of HCC Using Bioinformatics and the Hepatocyte Differentiation Model. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2557-6_18] [Reference Citation Analysis]
|
| 339 |
Liu X, Wu Z, Guo C, Guo H, Su Y, Chen Q, Sun C, Liu Q, Chen D, Mu H. Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy. Drug Deliv 2022;29:138-48. [PMID: 34967268 DOI: 10.1080/10717544.2021.2021324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 340 |
Carr BI, Bag HG, Ince V, Ogut Z, Tuncer A, Akbulut S, Ersan V, Usta S, Isik B, Yilmaz S. A simple 2-parameter blood test alert for the presence of small hepatocellular carcinomas. Clin Pract (Lond) 2021;18:1804-9. [PMID: 34966540] [Reference Citation Analysis]
|
| 341 |
Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 342 |
Wei XC, Xia YR, Zhou P, Xue X, Ding S, Liu LJ, Zhu F. Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma. World J Gastroenterol 2021; 27(48): 8302-8322 [DOI: 10.3748/wjg.v27.i48.8302] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 343 |
Yu Y, Chen X, Zhang W, Liu J. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression. Biomed Res Int 2021;2021:4051192. [PMID: 34957303 DOI: 10.1155/2021/4051192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 344 |
Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:615-28. [PMID: 34950184 DOI: 10.1159/000518048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 345 |
Jiang Z, Xing C, Wang P, Liu X, Zhong L. Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment. Front Cell Dev Biol 2021;9:748269. [PMID: 34938730 DOI: 10.3389/fcell.2021.748269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 346 |
García-Pras E, Fernández-Iglesias A, Gracia-Sancho J, Pérez-Del-Pulgar S. Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities. Cancers (Basel) 2021;14:48. [PMID: 35008212 DOI: 10.3390/cancers14010048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 347 |
Lin B, Wang Y, Zhao K, Lü WD, Hui X, Ma Y, Lv R. Exosome-based rare earth nanoparticles for targeted in situ and metastatic tumor imaging with chemo-assisted immunotherapy. Biomater Sci 2021. [PMID: 34940770 DOI: 10.1039/d1bm01809d] [Reference Citation Analysis]
|
| 348 |
Wang S, Wang X, Yang X, Liu F, Li J, Li W, Bai Z, Wang H, Mao J, Li T, He K, Wang H. Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. Proteomics 2021;:e2100141. [PMID: 34932872 DOI: 10.1002/pmic.202100141] [Reference Citation Analysis]
|
| 349 |
Wu ZH, Yang DL, Wang L, Liu J. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2021;12:793343. [PMID: 34925377 DOI: 10.3389/fimmu.2021.793343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 350 |
Zhang K, Li D, Zhou B, Liu J, Luo X, Wei R, Wang L, Hu X, Su Z, Lin H, Gao J, Shan H. Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC. Biomater Sci 2021;10:243-57. [PMID: 34846385 DOI: 10.1039/d1bm01374b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 351 |
Xie H, Alem Glison DM, Kim RD. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opin Investig Drugs 2021;:1-8. [PMID: 34913780 DOI: 10.1080/13543784.2022.2017879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 352 |
Feng X, Jiang T, Yang C, Pang S, Ding Z, Hu H, Wang H, Dong L, Yang N. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. Cell Death Dis 2021;13:6. [PMID: 34921137 DOI: 10.1038/s41419-021-04447-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 353 |
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu J, Liu S, Yu M, Chen J, Wang S, Zhang K, Tan Y, Han Z, Wei L, Zhang B, Cheng Z, Li L, Wang H. An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target Ther 2021;6:421. [PMID: 34916485 DOI: 10.1038/s41392-021-00801-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 354 |
Huang C, Zhang C, Sheng J, Wang D, Zhao Y, Qian L, Xie L, Meng Z. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:717319. [PMID: 34899826 DOI: 10.3389/fgene.2021.717319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 355 |
Shi J, Wu P, Sheng L, Sun W, Zhang H. Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma. Cancer Cell Int 2021;21:669. [PMID: 34906147 DOI: 10.1186/s12935-021-02389-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 356 |
Dzhanyan IA, Breder VV, Borisova OI, Laktionov KK. Рembrolizumab as second line therapy for hepatocellular patient. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-20-150-154] [Reference Citation Analysis]
|
| 357 |
Liu X, Zhang Y, Wang Z, Liu L, Zhang G, Li J, Ren Z, Dong Z, Yu Z. PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration. J Hepatocell Carcinoma 2021;8:1495-511. [PMID: 34881207 DOI: 10.2147/JHC.S337111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 358 |
Cao P, Ma B, Sun D, Zhang W, Qiu J, Qin L, Xue X. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis. Cancer Sci 2021. [PMID: 34890089 DOI: 10.1111/cas.15238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 359 |
Zhao G, Shi X, Sun Z, Zhao P, Lu Z. PAQR4 promotes the development of hepatocellular carcinoma by activating PI3K/AKT pathway. Acta Biochim Biophys Sin (Shanghai) 2021;53:1602-13. [PMID: 34718369 DOI: 10.1093/abbs/gmab143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 360 |
Wu ZH, Li ZW, Yang DL, Liu J. Development and Validation of a Pyroptosis-Related Long Non-coding RNA Signature for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:713925. [PMID: 34869306 DOI: 10.3389/fcell.2021.713925] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 361 |
Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 362 |
Huang H, Hou J, Liu K, Liu Q, Shen L, Liu B, Lu Q, Zhang N, Che L, Li J, Jiang S, Wang B, Wen Q, Hu L, Gao J. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance. J Gastroenterol Hepatol 2021;36:3429-37. [PMID: 34258777 DOI: 10.1111/jgh.15619] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 363 |
Kong D, Jiang Y, Miao X, Wu Z, Liu H, Gong W. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway. Biochim Biophys Acta Mol Basis Dis 2021;1867:166267. [PMID: 34508829 DOI: 10.1016/j.bbadis.2021.166267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 364 |
Pandit SK, Sandrini G, Merulla J, Nobili V, Wang X, Zangari A, Rinaldi A, Shinde D, Carbone GM, Catapano CV. Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6029. [PMID: 34885140 DOI: 10.3390/cancers13236029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 365 |
Zhou L, Zhang L, Chen S, Sun D, Qu J. Elevated Neddylation Pathway Promotes Th2 Cells Infiltration by Transactivating STAT5A in Hepatocellular Carcinoma. Front Oncol 2021;11:709170. [PMID: 34804916 DOI: 10.3389/fonc.2021.709170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 366 |
Romito I, Porru M, Braghini MR, Pompili L, Panera N, Crudele A, Gnani D, De Stefanis C, Scarsella M, Pomella S, Levi Mortera S, de Billy E, Conti AL, Marzano V, Putignani L, Vinciguerra M, Balsano C, Pastore A, Rota R, Tartaglia M, Leonetti C, Alisi A. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res 2021;40:364. [PMID: 34784956 DOI: 10.1186/s13046-021-02154-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 367 |
Zhu LR, Ni WJ, Cai M, Dai WT, Zhou H. Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies. Front Cell Dev Biol 2021;9:777007. [PMID: 34778277 DOI: 10.3389/fcell.2021.777007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 368 |
Liao W, Yang W, Xu J, Yan Z, Pan M, Xu X, Zhou S, Zhu Y, Lan J, Zeng M, Han X, Li S, Li Y, Liang K, Gao Y, Peng Q. Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening. Front Pharmacol 2021;12:658197. [PMID: 34776939 DOI: 10.3389/fphar.2021.658197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 369 |
Lin JC, Liu TP, Andriani V, Athoillah M, Wang CY, Yang PM. Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. J Pers Med 2021;11:1199. [PMID: 34834551 DOI: 10.3390/jpm11111199] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 370 |
Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, Peng T. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. J Hepatocell Carcinoma 2021;8:1323-38. [PMID: 34765572 DOI: 10.2147/JHC.S335425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 371 |
Carr BI, Bag HG, Ince V, Akbulut S, Ersan V, Usta S, Isik B, Ogut Z, Tuncer A, Yilmaz S. A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients. J Gastrointest Cancer 2021. [PMID: 34762264 DOI: 10.1007/s12029-021-00740-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 372 |
Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 373 |
Patra T, Meyer K, Ray RB, Kanda T, Ray R. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. Cell Death Dis 2021;12:1073. [PMID: 34759291 DOI: 10.1038/s41419-021-04371-7] [Reference Citation Analysis]
|
| 374 |
Cho K, Ro SW, Lee HW, Moon H, Han S, Kim HR, Ahn SH, Park JY, Kim DY. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. Hepatology 2021;74:2605-21. [PMID: 34101869 DOI: 10.1002/hep.32000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 375 |
Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 376 |
Li X, Zhen Y, Li S. Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. Materials & Design 2021;209:109958. [DOI: 10.1016/j.matdes.2021.109958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 377 |
Wu F, Xu L, Tu Y, Cheung OK, Szeto LL, Mok MT, Yang W, Kang W, Cao Q, Lai PB, Chan SL, Tan P, Sung JJ, Yip KY, Cheng AS, To KF. Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Lett 2021;525:115-30. [PMID: 34736960 DOI: 10.1016/j.canlet.2021.10.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 378 |
Xu Q, Chen S, Hu Y, Huang W. Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma. Cancer Cell Int 2021;21:582. [PMID: 34717651 DOI: 10.1186/s12935-021-02289-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 379 |
Ju M, Jiang L, Wei Q, Yu L, Chen L, Wang Y, Hu B, Qian P, Zhang M, Zhou C, Li Z, Wei M, Zhao L, Han J. A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer. Onco Targets Ther 2021;14:5065-83. [PMID: 34707365 DOI: 10.2147/OTT.S326784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 380 |
Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
|
| 381 |
Liu J, Huang L, Zhu Y, He Y, Zhang W, Lei T, Xuan J, Xiao B, Li L, Zhou Q, Sun Z. Exploring the Expression and Prognostic Value of the TCP1 Ring Complex in Hepatocellular Carcinoma and Overexpressing Its Subunit 5 Promotes HCC Tumorigenesis. Front Oncol 2021;11:739660. [PMID: 34676169 DOI: 10.3389/fonc.2021.739660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 382 |
Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 383 |
Khan MGM, Boufaied N, Yeganeh M, Ghosh A, Kandhi R, Bagheri R, Petkiewicz S, Sharma A, Yoshimura A, Ferbeyre G, Labbé DP, Ramanathan S, Ilangumaran S. SOCS3-mediated activation of p53-p21-NRF2 axis and cellular adaptation to oxidative stress in SOCS1-deficient hepatocellular carcinoma.. [DOI: 10.1101/2021.10.21.465149] [Reference Citation Analysis]
|
| 384 |
Guo J, Zhu P, Ye Z, Wang M, Yang H, Huang S, Shu Y, Zhang W, Zhou H, Li Q. YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS. Front Pharmacol 2021;12:744578. [PMID: 34658879 DOI: 10.3389/fphar.2021.744578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 385 |
Wang H, Yu S, Cai Q, Ma D, Yang L, Zhao J, Jiang L, Zhang X, Yu Z. The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:737723. [PMID: 34660596 DOI: 10.3389/fcell.2021.737723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 386 |
Cui D, Li W, Jiang D, Wu J, Xie J, Wu Y. Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:754709. [PMID: 34660653 DOI: 10.3389/fmed.2021.754709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 387 |
Zhang Y, Liu Z, Ji K, Li X, Wang C, Ren Z, Liu Y, Chen X, Han X, Meng L, Li L, Li Z. Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:736330. [PMID: 34660697 DOI: 10.3389/fmolb.2021.736330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 388 |
Rizzo A. Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al. Transl Oncol 2021;14:101246. [PMID: 34656968 DOI: 10.1016/j.tranon.2021.101246] [Reference Citation Analysis]
|
| 389 |
Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 390 |
Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, González-Regueiro JA, Kúsulas-Delint D, Campos-Murguía A, Flores-García NC, Macías-Rodríguez RU. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(10): 1440-1452 [PMID: 34721776 DOI: 10.4251/wjgo.v13.i10.1440] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 391 |
Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 392 |
Xu H, Chen K, Shang R, Chen X, Zhang Y, Song X, Evert M, Zhong S, Li B, Calvisi DF, Chen X. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death Dis 2021;12:920. [PMID: 34625531 DOI: 10.1038/s41419-021-04206-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 393 |
Kim MY, Lee H, Ji SY, Kim SY, Hwangbo H, Park SH, Kim GY, Park C, Leem SH, Hong SH, Choi YH. Induction of Apoptosis by Isoalantolactone in Human Hepatocellular Carcinoma Hep3B Cells through Activation of the ROS-Dependent JNK Signaling Pathway. Pharmaceutics 2021;13:1627. [PMID: 34683920 DOI: 10.3390/pharmaceutics13101627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 394 |
Savier E, Simon-Gracia L, Charlotte F, Tuffery P, Teesalu T, Scatton O, Rebollo A. Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics 2021;13:1631. [PMID: 34683924 DOI: 10.3390/pharmaceutics13101631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 395 |
Qin L, Huang D, Huang J, Qin F, Huang H. Integrated Analysis and Finding Reveal Anti-Liver Cancer Targets and Mechanisms of Pachyman (Poria cocos Polysaccharides). Front Pharmacol 2021;12:742349. [PMID: 34603055 DOI: 10.3389/fphar.2021.742349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 396 |
Liu S, Zhao W, Li X, Zhang, Gao Y, Peng Q, Du C, Jiang N. AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2021;11:713017. [PMID: 34595113 DOI: 10.3389/fonc.2021.713017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 397 |
Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 398 |
Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021;18:690-704. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 399 |
Niño-Ramírez S, Jaramillo-Arroyave D, Ardila O, Guevara-Casallas LG. Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. Rev Gastroenterol Mex (Engl Ed) 2021;86:356-62. [PMID: 34419411 DOI: 10.1016/j.rgmxen.2021.08.010] [Reference Citation Analysis]
|
| 400 |
Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021;75:865-78. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 401 |
Qiu C, Li Z, Cao W, Cai X, Ye L, Zhang C, Ma Y, Wang X, Yang Y. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203978. [PMID: 34435618 DOI: 10.1042/BSR20203978] [Reference Citation Analysis]
|
| 402 |
Jiao F, Guo R, Beckmann JS, Yan Z, Yang Y, Hu J, Wang X, Xie S. Great future or greedy venture: Precision medicine needs philosophy. Health Sci Rep 2021;4:e376. [PMID: 34541334 DOI: 10.1002/hsr2.376] [Reference Citation Analysis]
|
| 403 |
Sun Y, Liu S, Gao Y, Du Y, Cai H, Zhang J, Wang Z, Yang X, Hao L, Yan F. Decitabine-Loaded Gold Nanocages for Photothermal Cancer Therapy via DNA Hypermethylation Reversal. ACS Appl Nano Mater 2021;4:10556-64. [DOI: 10.1021/acsanm.1c02064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 404 |
Chen Z, Zou Y, Zhang Y, Chen Z, Wu F, Shi N, Jin H. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma. J Clin Lab Anal 2021;35:e24005. [PMID: 34523732 DOI: 10.1002/jcla.24005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 405 |
Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 406 |
Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
|
| 407 |
Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 408 |
Lin Z, Xie YZ, Zhao MC, Hou PP, Tang J, Chen GL. Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma. Cancer Cell Int 2021;21:475. [PMID: 34496841 DOI: 10.1186/s12935-021-02173-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 409 |
Lu X, Meng J, Zhou Y, Wang H, Ruan X, Chen Y, Ye Y, Su L, Fan X, Yan H, Jiang L, Yan F. DNA replication stress stratifies prognosis and enables exploitable therapeutic vulnerabilities of HBV-associated hepatocellular carcinoma: an in silico strategy towards precision oncology.. [DOI: 10.1101/2021.09.04.458962] [Reference Citation Analysis]
|
| 410 |
Wang H, Chen X, Calvisi DF. Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opin Ther Targets 2021;25:645-58. [PMID: 34477018 DOI: 10.1080/14728222.2021.1976142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 411 |
Qi F, Qin W, Zhang Y, Luo Y, Niu B, An Q, Yang B, Shi K, Yu Z, Chen J, Cao X, Xia J. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway. J Exp Clin Cancer Res 2021;40:280. [PMID: 34479623 DOI: 10.1186/s13046-021-02085-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 412 |
Yang F, Wan Y, Xu L, Wu Y, Shen X, Wang J, Lu D, Shao C, Zheng S, Niu T, Xu X. MRI-Radiomics Prediction for Cytokeratin 19-Positive Hepatocellular Carcinoma: A Multicenter Study. Front Oncol 2021;11:672126. [PMID: 34476208 DOI: 10.3389/fonc.2021.672126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 413 |
Liao H, Shi J, Wen K, Lin J, Liu Q, Shi B, Yan Y, Xiao Z. Molecular Targets of Ferroptosis in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:985-96. [PMID: 34466409 DOI: 10.2147/JHC.S325593] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 414 |
De la Pinta C. Toward Personalized Medicine in Radiotherapy of Hepatocellular Carcinoma: Emerging Radiomic Biomarker Candidates of Response and Toxicity. OMICS: A Journal of Integrative Biology 2021;25:537-544. [DOI: 10.1089/omi.2021.0065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 415 |
Shang R, Song X, Wang P, Zhou Y, Lu X, Wang J, Xu M, Chen X, Utpatel K, Che L, Liang B, Cigliano A, Evert M, Calvisi DF, Chen X. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut 2021;70:1746-57. [PMID: 33144318 DOI: 10.1136/gutjnl-2020-320716] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 416 |
Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, Cen B, Wei X, Wei Q, Xie H, Xu X. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chin J Cancer Res 2021;33:470-9. [PMID: 34584372 DOI: 10.21147/j.issn.1000-9604.2021.04.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 417 |
Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 418 |
Shen H, Liu B, Xu J, Zhang B, Wang Y, Shi L, Cai X. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. J Hematol Oncol 2021;14:134. [PMID: 34461958 DOI: 10.1186/s13045-021-01145-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 419 |
Zhang Z, Wang Z, Huang Y. Comprehensive Analyses of the Infiltrating Immune Cell Landscape and Its Clinical Significance in Hepatocellular Carcinoma. Int J Gen Med 2021;14:4695-704. [PMID: 34447264 DOI: 10.2147/IJGM.S326535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 420 |
Wang Y, Li N, Tian D, Zhou CW, Wang YH, Yang C, Zeng MS. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:6451-71. [PMID: 34429653 DOI: 10.2147/CMAR.S322179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 421 |
Vacani-Martins N, Meuser-Batista M, Dos Santos CLP, Hasslocher-Moreno AM, Henriques-Pons A. The Liver and the Hepatic Immune Response in Trypanosoma cruzi Infection, a Historical and Updated View. Pathogens 2021;10:1074. [PMID: 34578107 DOI: 10.3390/pathogens10091074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 422 |
Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 423 |
Akasu M, Shimada S, Kabashima A, Akiyama Y, Shimokawa M, Akahoshi K, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Sci Rep 2021;11:16732. [PMID: 34429454 DOI: 10.1038/s41598-021-96167-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 424 |
Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 425 |
An Y, Jiang J, Zhou L, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, Zou B, Xie N. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Lett 2021;521:210-23. [PMID: 34428517 DOI: 10.1016/j.canlet.2021.08.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 426 |
Ji GW, Fan Y, Sun DW, Wu MY, Wang K, Li XC, Wang XH. Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection. J Hepatocell Carcinoma 2021;8:913-23. [PMID: 34414136 DOI: 10.2147/JHC.S320172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 427 |
Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 428 |
Ju G, Zhou T, Zhang R, Pan X, Xue B, Miao S. DUSP12 regulates the tumorigenesis and prognosis of hepatocellular carcinoma. PeerJ 2021;9:e11929. [PMID: 34414037 DOI: 10.7717/peerj.11929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 429 |
Chen L, Sun L, Dai X, Li T, Yan X, Zhang Y, Xiao H, Shen X, Huang G, Xiang W, Zhang Y, Tan D, Yang S, Nie Y, Huang X, Lian J, He F. LncRNA CRNDE Promotes ATG4B-Mediated Autophagy and Alleviates the Sensitivity of Sorafenib in Hepatocellular Carcinoma Cells. Front Cell Dev Biol 2021;9:687524. [PMID: 34409031 DOI: 10.3389/fcell.2021.687524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 430 |
Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:615-28. [PMID: 34950184 DOI: 10.1159/000518048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 431 |
Wang A, Chen X, Li D, Yang L, Jiang J. METTL3-mediated m6A methylation of ASPM drives hepatocellular carcinoma cells growth and metastasis. J Clin Lab Anal 2021;35:e23931. [PMID: 34398984 DOI: 10.1002/jcla.23931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 432 |
Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol 2021;19:241. [PMID: 34389000 DOI: 10.1186/s12957-021-02354-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 433 |
Zhu H, Huang M, Luo J, Ji X, Liu Q. Deficiency of GFRα1 promotes hepatocellular carcinoma progression but enhances oxaliplatin-mediated anti-tumor efficacy. Pharmacol Res 2021;172:105815. [PMID: 34391932 DOI: 10.1016/j.phrs.2021.105815] [Reference Citation Analysis]
|
| 434 |
Mu H, Yu G, Li H, Wang M, Cui Y, Zhang T, Song T, Liu C. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation. Cell Oncol (Dordr) 2021. [PMID: 34339013 DOI: 10.1007/s13402-021-00625-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 435 |
Lei J, Zhang D, Yao C, Ding S, Lu Z. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis. Cancer Control. 2020;27:1073274820977114. [PMID: 33269615 DOI: 10.1177/1073274820977114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 436 |
Borhani AA, Catania R, Velichko YS, Hectors S, Taouli B, Lewis S. Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response. Abdom Radiol (NY) 2021;46:3674-85. [PMID: 33891149 DOI: 10.1007/s00261-021-03085-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 437 |
Komiyama S, Numata K, Ogushi K, Chuma M, Tanaka R, Chiba S, Otani M, Inayama Y, Nakano M, Maeda S. Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. Diagnostics (Basel) 2021;11:1394. [PMID: 34441328 DOI: 10.3390/diagnostics11081394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 438 |
Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
|
| 439 |
Xiong DL, Li Q, Wang H, Jin WL, Fan XM, Ma YY. High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma. Cancer Biomark 2021. [PMID: 34366322 DOI: 10.3233/CBM-203248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 440 |
Jing T, Wang B, Yang Z, Liu Y, Xu G, Xu X, Jiao K, Chen Z, Xiang L, Zhang L, Liu Y. Deubiquitination of the repressor E2F6 by USP22 facilitates AKT activation and tumor growth in hepatocellular carcinoma. Cancer Lett 2021;518:266-77. [PMID: 34339800 DOI: 10.1016/j.canlet.2021.07.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 441 |
Wang J, Wang Y, Xu J, Song Q, Shangguan J, Xue M, Wang H, Gan J, Gao W. Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma. Sci Prog 2021;104:368504211029429. [PMID: 34315286 DOI: 10.1177/00368504211029429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 442 |
Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World J Clin Cases 2021; 9(21): 5988-5998 [PMID: 34368318 DOI: 10.12998/wjcc.v9.i21.5988] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 443 |
Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 444 |
Rudalska R, Zender L, Dauch D. Exploiting lipotoxicity for the treatment of liver cancer. Br J Cancer 2021. [PMID: 34302061 DOI: 10.1038/s41416-021-01479-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 445 |
Wang R, Lin N, Mao B, Wu Q. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. J Cancer Res Clin Oncol 2021. [PMID: 34297207 DOI: 10.1007/s00432-021-03716-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 446 |
Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 447 |
Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med 2021;10:3201. [PMID: 34361985 DOI: 10.3390/jcm10153201] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 448 |
Choi GH, Jang ES, Kim JW, Jeong SH. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol 2021; 27(27): 4453-4467 [PMID: 34366616 DOI: 10.3748/wjg.v27.i27.4453] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 449 |
Kubo A, Suda G, Kimura M, Maehara O, Tokuchi Y, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers (Basel) 2021;13:3633. [PMID: 34298844 DOI: 10.3390/cancers13143633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 450 |
Zhan K, Bai Y, Liao S, Chen H, Kuang L, Luo Q, Lv L, Qiu L, Mei Z. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma. Mol Med Rep 2021;24:650. [PMID: 34278494 DOI: 10.3892/mmr.2021.12289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 451 |
Mir IH, Guha S, Behera J, Thirunavukkarasu C. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biol Int 2021. [PMID: 34270844 DOI: 10.1002/cbin.11670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 452 |
Lee J, Hwang JH, Chun H, Woo W, Oh S, Choi J, Kim LK. PLEKHA8P1 Promotes Tumor Progression and Indicates Poor Prognosis of Liver Cancer. Int J Mol Sci 2021;22:7614. [PMID: 34299245 DOI: 10.3390/ijms22147614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 453 |
Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D'yachkova Y, Lukanowski M, Cheng R, Chen LT. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers? Cancers (Basel) 2021;13:3536. [PMID: 34298750 DOI: 10.3390/cancers13143536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 454 |
Wang L, Wang L, Wang S, Zhou Z, Liu Z, Xu P, Luo X, Wu T, Luo F, Yan J. N2E4, a Monoclonal Antibody Targeting Neuropilin-2, Inhibits Tumor Growth and Metastasis in Pancreatic Ductal Adenocarcinoma via Suppressing FAK/Erk/HIF-1α Signaling. Front Oncol 2021;11:657008. [PMID: 34336654 DOI: 10.3389/fonc.2021.657008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 455 |
Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
|
| 456 |
Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 457 |
Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 458 |
Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 459 |
Moser M, Radu IP, Dufour JF. Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open 2021;5:864-70. [PMID: 34386593 DOI: 10.1002/jgh3.12533] [Reference Citation Analysis]
|
| 460 |
Qiu MJ, Zhang L, Chen YB, Zhu LS, Zhang B, Li QT, Yang SL, Xiong ZF. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. Int J Biochem Cell Biol 2021;137:106037. [PMID: 34217812 DOI: 10.1016/j.biocel.2021.106037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 461 |
Jiang T, Sánchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology 2021;74:233-47. [PMID: 33336367 DOI: 10.1002/hep.31685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 462 |
Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 463 |
Lin X, Xiang X, Feng B, Zhou H, Wang T, Chu X, Wang R. Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects. Front Oncol 2021;11:670838. [PMID: 34249710 DOI: 10.3389/fonc.2021.670838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 464 |
Chen MH, Fu LS, Zhang F, Yang Y, Wu XZ. LncAY controls BMI1 expression and activates BMI1/Wnt/β-catenin signaling axis in hepatocellular carcinoma. Life Sci 2021;280:119748. [PMID: 34174322 DOI: 10.1016/j.lfs.2021.119748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 465 |
Fontemaggi G, Turco C, Esposito G, Di Agostino S. New Molecular Mechanisms and Clinical Impact of circRNAs in Human Cancer. Cancers (Basel) 2021;13:3154. [PMID: 34202482 DOI: 10.3390/cancers13133154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 466 |
Lambrecht C, Ferreira GB, Omella JD, Libbrecht L, DE Vos R, Derua R, Mathieu C, Overbergh L, Waelkens E, Janssens V. Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers. Cancer Genomics Proteomics 2020;17:669-85. [PMID: 33099469 DOI: 10.21873/cgp.20222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 467 |
Ho DW, Tsui YM, Chan LK, Sze KM, Zhang X, Cheu JW, Chiu YT, Lee JM, Chan AC, Cheung ET, Yau DT, Chia NH, Lo IL, Sham PC, Cheung TT, Wong CC, Ng IO. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun 2021;12:3684. [PMID: 34140495 DOI: 10.1038/s41467-021-24010-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 468 |
Ho DW, Tsui YM, Chan LK, Sze KM, Zhang X, Cheu JW, Chiu YT, Lee JM, Chan AC, Cheung ET, Yau DT, Chia NH, Lo IL, Sham PC, Cheung TT, Wong CC, Ng IO. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun 2021;12:3684. [PMID: 34140495 DOI: 10.1038/s41467-021-24010-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 469 |
Taranto D, Ramirez CFA, Vegna S, de Groot MHP, de Wit N, Van Baalen M, Klarenbeek S, Akkari L. Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment. Curr Protoc 2021;1:e147. [PMID: 34101385 DOI: 10.1002/cpz1.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 470 |
Kant R, Yang MH, Tseng CH, Yen CH, Li WY, Tyan YC, Chen M, Tzeng CC, Chen WC, You K, Wang WC, Chen YL, Chen YA. Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis. J Med Chem 2021;64:8992-9009. [PMID: 34132534 DOI: 10.1021/acs.jmedchem.1c00093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 471 |
Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 472 |
Liang J, Zhi Y, Deng W, Zhou W, Li X, Cai Z, Zhu Z, Zeng J, Wu W, Dong Y, Huang J, Zhang Y, Xu S, Feng Y, Ding F, Zhang J. Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma. PeerJ 2021;9:e11627. [PMID: 34178478 DOI: 10.7717/peerj.11627] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 473 |
Suo Z, Sun Q, Peng X, Zhang S, Gan N, Zhao L, Yuan N, Zhang Y, Li H. Lentinan as a natural stabilizer with bioactivities for preparation of drug-drug nanosuspensions. Int J Biol Macromol 2021;184:101-8. [PMID: 34119545 DOI: 10.1016/j.ijbiomac.2021.06.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 474 |
Pomyen Y, Budhu A, Chaisaingmongkol J, Forgues M, Dang H, Ruchirawat M, Mahidol C, Wang XW; TIGER-LC Consortium. Tumor metabolism and associated serum metabolites define prognostic subtypes of Asian hepatocellular carcinoma. Sci Rep 2021;11:12097. [PMID: 34103600 DOI: 10.1038/s41598-021-91560-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 475 |
Luo X, Cao M, Gao F, He X. YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Exp Hematol Oncol 2021;10:35. [PMID: 34088349 DOI: 10.1186/s40164-021-00227-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 476 |
Li W, Liu J, Ma Z, Zhai X, Cheng B, Zhao H. m6A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma. Dis Markers 2021;2021:8859590. [PMID: 34234878 DOI: 10.1155/2021/8859590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 477 |
Zheng Y, Cheng Y, Zhang C, Fu S, He G, Cai L, Qiu L, Huang K, Chen Q, Xie W, Chen T, Huang M, Bai Y, Pan M. Co-amplification of genes in chromosome 8q24: a robust prognostic marker in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1086-100. [PMID: 34295559 DOI: 10.21037/jgo-21-205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 478 |
Yang S, Liu Y, Xiao Z, Tang Y, Hong P, Sun S, Zhou C, Qian Z. Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK signaling pathways. Arabian Journal of Chemistry 2021;14:103187. [DOI: 10.1016/j.arabjc.2021.103187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 479 |
Gracia-Sancho J, Caparrós E, Fernández-Iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:411-31. [PMID: 33589830 DOI: 10.1038/s41575-020-00411-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 480 |
Ma G, Du X, Zhu J, Xu F, Yu H, Li J. Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. Journal of Drug Delivery Science and Technology 2021;63:102493. [DOI: 10.1016/j.jddst.2021.102493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 481 |
Yi Y, Yu MC, Fu PY, Liu G, Zhou PY, Guan RY, Zhou C, Sun BY, Qiu SJ. MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β-catenin and predicts poor prognosis. Liver Int 2021;41:1409-20. [PMID: 33506565 DOI: 10.1111/liv.14803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 482 |
Shi M, Lan S, Zhang C, Xiong W, Li Q, Maimaiti T, Liu F, Liang C, Wu X, Yang ST. Biocompatible zinc gallogermanate persistent luminescent nanoparticles for fast tumor drainage lymph node imaging in vivo. Colloids Surf B Biointerfaces 2021;205:111887. [PMID: 34091370 DOI: 10.1016/j.colsurfb.2021.111887] [Reference Citation Analysis]
|
| 483 |
Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Cited by in Crossref: 40] [Cited by in F6Publishing: 56] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 484 |
Xu Q, Hu Y, Chen S, Zhu Y, Li S, Shen F, Guo Y, Sun T, Chen X, Jiang J, Huang W. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:683240. [PMID: 34124163 DOI: 10.3389/fmolb.2021.683240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 485 |
Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 486 |
Lin JC, Liu CL, Chang YC, Cheng SP, Huang WC, Lin CH, Wu CY, Chen MJ. Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib. Invest New Drugs 2021. [PMID: 34031786 DOI: 10.1007/s10637-021-01132-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 487 |
Iijima K, Nakamura H, Takada K, Hayasaka N, Kubo T, Umeyama Y, Iyama S, Miyanishi K, Kobune M, Kato J. Six-transmembrane epithelial antigen of the prostate 1 accelerates cell proliferation by targeting c-Myc in liver cancer cells. Oncol Lett 2021;22:546. [PMID: 34335918 DOI: 10.3892/ol.2021.12807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 488 |
Guan X, Lu Y, Zhu H, Yu S, Zhao W, Chi X, Xie C, Yin Z. The Crosstalk Between Cancer Cells and Neutrophils Enhances Hepatocellular Carcinoma Metastasis via Neutrophil Extracellular Traps-Associated Cathepsin G Component: A Potential Therapeutic Target. J Hepatocell Carcinoma 2021;8:451-65. [PMID: 34046369 DOI: 10.2147/JHC.S303588] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 489 |
Fang C, Xie H, Zhao J, Wang W, Hou H, Zhang B, Zhou D, Geng X. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. Anticancer Drugs 2021;32:822-8. [PMID: 33783376 DOI: 10.1097/CAD.0000000000001074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 490 |
Yu AT, Berasain C, Bhatia S, Rivera K, Liu B, Rigo F, Pappin DJ, Spector DL. PHAROH lncRNA regulates Myc translation in hepatocellular carcinoma via sequestering TIAR. Elife 2021;10:e68263. [PMID: 34002693 DOI: 10.7554/eLife.68263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 491 |
Tian H, Huang Y, He J, Zhang M, Ni P. CD147 Monoclonal Antibody Targeted Reduction-Responsive Camptothecin Polyphosphoester Nanomedicine for Drug Delivery in Hepatocellular Carcinoma Cells. ACS Appl Bio Mater 2021;4:4422-31. [PMID: 35006854 DOI: 10.1021/acsabm.1c00177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 492 |
Liu QQ, Liu YW, Xie YK, Zhang JH, Song CX, Wang JZ, Xie BH. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma. Cell Biol Int 2021;45:1906-16. [PMID: 33969575 DOI: 10.1002/cbin.11625] [Reference Citation Analysis]
|
| 493 |
El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev 2021;98:102221. [PMID: 34029957 DOI: 10.1016/j.ctrv.2021.102221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 494 |
Fan Y, Yu Y, Wang X, Hu M, Du M, Guo L, Sun S, Hu C. Texture Analysis Based on Gd-EOB-DTPA-Enhanced MRI for Identifying Vessels Encapsulating Tumor Clusters (VETC)-Positive Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:349-59. [PMID: 33981636 DOI: 10.2147/JHC.S293755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 495 |
Streubel G, Schrepfer S, Kallus H, Parnitzke U, Wulff T, Hermann F, Borgmann M, Hamm S. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Sci Rep 2021;11:9587. [PMID: 33953226 DOI: 10.1038/s41598-021-88983-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 496 |
Xia S, Ji L, Tao L, Pan Y, Lin Z, Wan Z, Pan H, Zhao J, Cai L, Xu J, Cai X. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cell Mol Gastroenterol Hepatol 2021;12:1121-43. [PMID: 33962073 DOI: 10.1016/j.jcmgh.2021.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 497 |
Xiong C, Wang Z, Wang G, Zhang C, Jin S, Jiang G, Bai D. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma. Invest New Drugs 2021. [PMID: 33942202 DOI: 10.1007/s10637-021-01126-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 498 |
Chen H, Nio K, Yamashita T, Okada H, Li R, Suda T, Li Y, Doan PTB, Seki A, Nakagawa H, Toyama T, Terashima T, Iida N, Shimakami T, Takatori H, Kawaguchi K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. Mol Oncol 2021;15:2203-18. [PMID: 33834612 DOI: 10.1002/1878-0261.12963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 499 |
Saberi B, Naik H, Overbey JR, Erwin AL, Anderson KE, Bissell DM, Bonkovsky HL, Phillips JD, Wang B, K Singal A, M McGuire B, Desnick RJ, Balwani M. Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology 2021;73:1736-46. [PMID: 32681675 DOI: 10.1002/hep.31460] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 500 |
Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 174] [Cited by in F6Publishing: 164] [Article Influence: 87.0] [Reference Citation Analysis]
|
| 501 |
Chen Y, Song S, Zhang L, Zhang Y. Circular RNA hsa_circ_0091579 facilitates the Warburg effect and malignancy of hepatocellular carcinoma cells via the miR-624/H3F3B axis. Clin Transl Oncol 2021. [PMID: 33934291 DOI: 10.1007/s12094-021-02627-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 502 |
Ragusa F, Panera N, Cardarelli S, Scarsella M, Bianchi M, Biagioni S, Giorgi M, Alisi A, Massimi M. Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2182. [PMID: 34062786 DOI: 10.3390/cancers13092182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 503 |
Xin F, Wu M, Cai Z, Zhang X, Wei Z, Liu X, Liu J. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma. Adv Healthc Mater 2021;10:e2002036. [PMID: 33644987 DOI: 10.1002/adhm.202002036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 504 |
Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang K, Tang N. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis 2021;12:426. [PMID: 33931597 DOI: 10.1038/s41419-021-03718-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 505 |
Hou GM, Liu HL, Wu H, Zeng Y. Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. Ann Surg Oncol 2021. [PMID: 33900502 DOI: 10.1245/s10434-021-09949-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 506 |
Liu Y, Tan M, Fang C, Chen X, Liu H, Feng Y, Zhang Y, Min W. A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer. Nanotechnology 2021;32:175101. [PMID: 33445163 DOI: 10.1088/1361-6528/abdbed] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 507 |
Giannopoulou AF, Velentzas AD, Anagnostopoulos AK, Agalou A, Papandreou NC, Katarachia SA, Koumoundourou DG, Konstantakou EG, Pantazopoulou VI, Delis A, Michailidi MT, Valakos D, Chatzopoulos D, Syntichaki P, Iconomidou VA, Tsitsilonis OE, Papassideri IS, Voutsinas GE, Hatzopoulos P, Thanos D, Beis D, Anastasiadou E, Tsangaris GT, Stravopodis DJ. From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers (Basel) 2021;13:2024. [PMID: 33922182 DOI: 10.3390/cancers13092024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 508 |
Bai Y, Lin H, Chen J, Wu Y, Yu S. Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma. Front Mol Biosci 2021;8:645084. [PMID: 33968985 DOI: 10.3389/fmolb.2021.645084] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 509 |
Qiu S, Zhong C, Zhao B, Li G, Wang J, Jehan S, Li J, Zhao X, Li D, Sui G. Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells. Biochim Biophys Acta Gen Subj 2021;1865:129911. [PMID: 33862123 DOI: 10.1016/j.bbagen.2021.129911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 510 |
Yang X, Feng Y, Liu Y, Ye X, Ji X, Sun L, Gao F, Zhang Q, Li Y, Zhu B, Wang X. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine 2021;87:153575. [PMID: 33984593 DOI: 10.1016/j.phymed.2021.153575] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 511 |
Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 512 |
Hu J, Cai D, Zhao Z, Zhong GC, Gong J. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Front Oncol 2021;11:659676. [PMID: 33937074 DOI: 10.3389/fonc.2021.659676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 513 |
Ma T, Ma Y, Du Y, Wei Z, Wang J, Jun Y, Xiao F. Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma. Front Oncol 2021;11:585172. [PMID: 33937016 DOI: 10.3389/fonc.2021.585172] [Reference Citation Analysis]
|
| 514 |
Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, Chen Z, Meng Z. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma. Biosci Rep 2020;40:BSR20194240. [PMID: 32579175 DOI: 10.1042/BSR20194240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 515 |
Xue D, Han J, Liu Y, Tuo H, Peng Y. Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review). Cancer Biol Ther 2021;22:279-90. [PMID: 33847207 DOI: 10.1080/15384047.2021.1898728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 516 |
Gu X, Zhang S, Zhang T. Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity. Cells 2021;10:869. [PMID: 33921219 DOI: 10.3390/cells10040869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 517 |
Watanabe Y, Tanabe A, Hamakubo T, Nagatoishi S, Tsumoto K. Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells. J Biochem 2021:mvab049. [PMID: 33844018 DOI: 10.1093/jb/mvab049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 518 |
Wang X, Qiao J, Wang R. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20203263. [PMID: 33111935 DOI: 10.1042/BSR20203263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 519 |
Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK. Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 2021;5:zrab005. [PMID: 33839747 DOI: 10.1093/bjsopen/zrab005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 520 |
Oversoe SK, Clement MS, Weber B, Grønbæk H, Hamilton-Dutoit SJ, Sorensen BS, Kelsen J. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer 2021;21:376. [PMID: 33827453 DOI: 10.1186/s12885-021-08103-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 521 |
Lin B, Dong X, Wang Q, Li W, Zhu M, Li M. AFP-Inhibiting Fragments for Drug Delivery: The Promise and Challenges of Targeting Therapeutics to Cancers. Front Cell Dev Biol 2021;9:635476. [PMID: 33898423 DOI: 10.3389/fcell.2021.635476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 522 |
Zhang YF, Wang YX, Zhang N, Lin ZH, Wang LR, Feng Y, Pan Q, Wang L. Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma. Bioengineered 2021;12:1202-11. [PMID: 33830865 DOI: 10.1080/21655979.2021.1908812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 523 |
Guo JC, Liu Z, Yang YJ, Guo M, Zhang JQ, Zheng JF. KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis. J Cell Mol Med 2021. [PMID: 33829656 DOI: 10.1111/jcmm.16342] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 524 |
Li Q, Sun M, Wang M, Feng M, Yang F, Li L, Zhao J, Chang C, Dong H, Xie T, Chen J. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci 2021;112:1695-706. [PMID: 33605517 DOI: 10.1111/cas.14861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 525 |
Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 2021;13:637-44. [PMID: 33820447 DOI: 10.2217/imt-2021-0026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 526 |
Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 527 |
Hua HW, Jiang HS, Jia L, Jia YP, Yao YL, Chen YW, Jiang F, Lu DQ, Zhou Q, Jiang MW, Ding G. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma. Cancer Biomark 2021. [PMID: 33843664 DOI: 10.3233/CBM-200101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 528 |
Kudo M. Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer 2021;10:85-93. [PMID: 33977086 DOI: 10.1159/000514312] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 529 |
Böttcher K, Longato L, Marrone G, Mazza G, Ghemtio L, Hall A, Luong TV, Caruso S, Viollet B, Zucman-Rossi J, Pinzani M, Rombouts K. AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. Am J Physiol Gastrointest Liver Physiol 2021;320:G543-56. [PMID: 33406006 DOI: 10.1152/ajpgi.00262.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 530 |
Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 531 |
Yamada R, Gayed A. Adding Sorafenib-eluting Microspheres to TACE: The Next Step in Hepatocellular Carcinoma Treatment. Radiol Imaging Cancer 2021;3:e200132. [PMID: 33778759 DOI: 10.1148/rycan.2021200132] [Reference Citation Analysis]
|
| 532 |
Montasser A, Beaufrère A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, Paradis V. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021;79:36-46. [PMID: 33326644 DOI: 10.1111/his.14317] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 533 |
Xu M, Xu J, Zhu D, Su R, Zhuang B, Xu R, Li L, Chen S, Ling Y. Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma. J Transl Med 2021;19:126. [PMID: 33771165 DOI: 10.1186/s12967-021-02792-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 534 |
Li H, Huang H, Li S, Mei H, Cao T, Lu Q. Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion. Exp Ther Med 2021;21:559. [PMID: 33850531 DOI: 10.3892/etm.2021.9991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 535 |
Wu J, Zhang T, Chen Y, Ha S. MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression. Biosci Rep 2020;40:BSR20193295. [PMID: 32285917 DOI: 10.1042/BSR20193295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 536 |
Zheng J, Zeng L, Tang M, Lin H, Pi C, Xu R, Cui X. Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3097. [PMID: 33803555 DOI: 10.3390/ijms22063097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 537 |
Niño-Ramírez S, Jaramillo-Arroyave D, Ardila O, Guevara-Casallas LG. Reducing the heterogeneity in hepatocellular carcinoma. A cluster analysis based on clinical variables in patients treated at a quaternary care hospital. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00011-2. [PMID: 33745755 DOI: 10.1016/j.rgmx.2020.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 538 |
Rodríguez MM, Onorato A, Cantero MJ, Domínguez L, Bayo J, Fiore E, García M, Atorrasagasti C, Canbay A, Malvicini M, Mazzolini GD. 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Sci Rep 2021;11:6310. [PMID: 33737571 DOI: 10.1038/s41598-021-85491-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 539 |
Wang Y, Liu D, Zhang T, Xia L. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers (Basel) 2021;13:1360. [PMID: 33802841 DOI: 10.3390/cancers13061360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 540 |
Jiang J, Liu B, Liu R, Yang W. Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Manag Res 2021;13:2517-37. [PMID: 33758547 DOI: 10.2147/CMAR.S296069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 541 |
Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021;12:2933-51. [PMID: 33854594 DOI: 10.7150/jca.52187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 542 |
Zhang C, Ke Y, Lei X, Liu X, Li H, Shi R, Wang L. The relationship among Girdin DNA methylation, its high expression, and immune infiltration in hepatocellular carcinoma: Clues from in silico analysis. Biosci Rep 2021;41:BSR20204006. [PMID: 33660763 DOI: 10.1042/BSR20204006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 543 |
Zhu G, Xia H, Tang Q, Bi F. An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. Cancer Cell Int 2021;21:166. [PMID: 33712026 DOI: 10.1186/s12935-021-01864-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 544 |
Zhang L, Chai Z, Kong S, Feng J, Wu M, Tan J, Yuan M, Chen G, Li Z, Zhou H, Cheng S, Xu H. Nujiangexanthone A Inhibits Hepatocellular Carcinoma Metastasis via Down Regulation of Cofilin 1. Front Cell Dev Biol 2021;9:644716. [PMID: 33791303 DOI: 10.3389/fcell.2021.644716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 545 |
Jiang SS, Ke SJ, Ke ZL, Li J, Li X, Xie XW. Cell Division Cycle Associated Genes as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:657161. [PMID: 33778011 DOI: 10.3389/fmolb.2021.657161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 546 |
Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 547 |
Xie X, Jiang S, Li X. Nuf2 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Hepatocellular Carcinoma. Front Oncol 2021;11:621373. [PMID: 33767990 DOI: 10.3389/fonc.2021.621373] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 548 |
Chen J, Jia X, Li Z, Song W, Jin C, Zhou M, Xie H, Zheng S, Song P. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma. Biochem Pharmacol 2021;188:114494. [PMID: 33684390 DOI: 10.1016/j.bcp.2021.114494] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 549 |
Zhang Q, Xing W, Zhang J, Hu J, Qi L, Xiang B. Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma. Onco Targets Ther 2021;14:1543-52. [PMID: 33688202 DOI: 10.2147/OTT.S298576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 550 |
Ferrarese A, Sciarrone SS, Pellone M, Shalaby S, Battistella S, Zanetto A, Germani G, Russo FP, Senzolo M, Burra P, Gambato M. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02775-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 551 |
Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 552 |
Burra P. Management of complex liver diseases. Minerva Gastroenterol (Torino) 2021;67:2-3. [PMID: 33784806 DOI: 10.23736/S2724-5985.20.02803-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 553 |
Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int 2021;41:598-607. [PMID: 33188713 DOI: 10.1111/liv.14731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 554 |
Ke W, Wang H, Zhao X, Lu Z. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food Funct 2021;12:1482-97. [PMID: 33502415 DOI: 10.1039/d0fo02243h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 555 |
Liu Y, Chen H, Li X, Zhang F, Kong L, Wang X, Bai J, Wu X. PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Front Oncol 2021;11:607021. [PMID: 33718159 DOI: 10.3389/fonc.2021.607021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 556 |
Cao J, Wu L, Lei X, Shi K, Shi L, Shi Y. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma. Bioengineered 2021;12:673-81. [PMID: 33622186 DOI: 10.1080/21655979.2021.1878763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 557 |
Zhang Q, Qiao L, Liao J, Liu Q, Liu P, Liu L. A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma. J Cell Mol Med 2021;25:3772-84. [PMID: 33616276 DOI: 10.1111/jcmm.16249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 558 |
Gao X, Huang H, Wang Y, Pan C, Yin S, Zhou L, Zheng S. Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Front Oncol 2020;10:610513. [PMID: 33680932 DOI: 10.3389/fonc.2020.610513] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 559 |
Zheng N, Zhang S, Wu W, Zhang N, Wang J. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. Pharmacol Res 2021;166:105507. [PMID: 33610718 DOI: 10.1016/j.phrs.2021.105507] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 560 |
Zhou J, Wang W, Li Q. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. J Exp Clin Cancer Res 2021;40:73. [PMID: 33596985 DOI: 10.1186/s13046-021-01873-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 561 |
Perrin-Cocon L, Vidalain PO, Jacquemin C, Aublin-Gex A, Olmstead K, Panthu B, Rautureau GJP, André P, Nyczka P, Hütt MT, Amoedo N, Rossignol R, Filipp FV, Lotteau V, Diaz O. A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity. Commun Biol 2021;4:217. [PMID: 33594203 DOI: 10.1038/s42003-021-01749-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 562 |
Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 563 |
Krstic J, Reinisch I, Schindlmaier K, Galhuber M, Berger N, Kupper N, Moyschewitz E, Auer M, Michenthaler H, Nössing C, Depaoli MR, Ramadani-muja J, Stryeck S, Pichler M, Rinner B, Deutsch AJ, Reinisch A, Madl T, Chiozzi RZ, Heck AJ, Huch M, Malli R, Prokesch A. Fasting reverses drug-resistance in hepatocellular carcinoma through p53-dependent metabolic synergism.. [DOI: 10.1101/2021.02.10.430545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 564 |
Cetin B, Gumusay O. Understanding relevant immune mechanisms in gastrointestinal oncology. J Oncol Pharm Pract 2021;27:1222-34. [PMID: 33557689 DOI: 10.1177/1078155221992862] [Reference Citation Analysis]
|
| 565 |
Feng P, Li H, Pei J, Huang Y, Li G. Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL). Front Genet 2021;12:625414. [PMID: 33643388 DOI: 10.3389/fgene.2021.625414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 566 |
Meng F, Liu J, Lu T, Zang L, Wang J, He Q, Zhou A. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics 2021;21:264-77. [PMID: 34095464 DOI: 10.1016/j.omto.2021.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 567 |
Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 2021;124:1388-97. [PMID: 33531690 DOI: 10.1038/s41416-021-01260-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 568 |
Cao R, Liu H, Cheng Z. Radiolabeled Peptide Probes for Liver Cancer Imaging. Curr Med Chem 2020;27:6968-86. [PMID: 32196443 DOI: 10.2174/0929867327666200320153837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 569 |
Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun 2021;27:100328. [PMID: 33549983 DOI: 10.1016/j.ctarc.2021.100328] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 27.5] [Reference Citation Analysis]
|
| 570 |
Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, Shi H, Wang JG, Zhou J, Lu GD. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin 2021;42:301-10. [PMID: 32699265 DOI: 10.1038/s41401-020-0478-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 571 |
Rudalska R, Harbig J, Snaebjornsson MT, Klotz S, Zwirner S, Taranets L, Heinzmann F, Kronenberger T, Forster M, Cui W, D'Artista L, Einig E, Hinterleitner M, Schmitz W, Dylawerska A, Kang TW, Poso A, Rosenfeldt MT, Malek NP, Bitzer M, Laufer S, Pichler BJ, Popov N, Schulze A, Zender L, Dauch D. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2021;2:201-17. [PMID: 35122079 DOI: 10.1038/s43018-020-00168-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 572 |
Sun X, Shi M, Zhang C, Yuan J, Yin M, Du S, Yu S, Ouyang B, Xue F, Yang S. Fluorescent Ag–In–S/ZnS Quantum Dots for Tumor Drainage Lymph Node Imaging In Vivo. ACS Appl Nano Mater 2021;4:1029-37. [DOI: 10.1021/acsanm.0c02542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 573 |
Zhang T, Liu D, Wang Y, Sun M, Xia L. The E-Twenty-Six Family in Hepatocellular Carcinoma: Moving into the Spotlight. Front Oncol 2020;10:620352. [PMID: 33585247 DOI: 10.3389/fonc.2020.620352] [Reference Citation Analysis]
|
| 574 |
Zhang Y, Zhai Q, Feng X, Chen D, Lu Y, Hu J, Xie H, Zhou L, Wu J, Zheng S. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma. Clin Transl Oncol 2021;23:1314-24. [PMID: 33502741 DOI: 10.1007/s12094-020-02519-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 575 |
Peng JL, Wu JZ, Li GJ, Wu JL, Xi YM, Li XQ, Wang L. Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24172. [PMID: 33466191 DOI: 10.1097/MD.0000000000024172] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 576 |
Sun L, Lin Y, Wang G, Zhang L, Hu L, Lu Z. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer. Biosci Rep 2021;41:BSR20203115. [PMID: 33439969 DOI: 10.1042/BSR20203115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 577 |
Haruna Y, Yakushijin T, Kawamoto S. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study. Cancer Med 2021;10:914-22. [PMID: 33481328 DOI: 10.1002/cam4.3674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 578 |
Tao P, Hong L, Tang W, Lu Q, Zhao Y, Zhang S, Ma L, Xue R. Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. Front Oncol 2020;10:574778. [PMID: 33552954 DOI: 10.3389/fonc.2020.574778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 579 |
Xu Q, Wang Y, Huang W. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol 2021;92:107333. [PMID: 33486322 DOI: 10.1016/j.intimp.2020.107333] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 580 |
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 1323] [Article Influence: 661.5] [Reference Citation Analysis]
|
| 581 |
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 1343] [Cited by in F6Publishing: 1328] [Article Influence: 671.5] [Reference Citation Analysis]
|
| 582 |
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 1323] [Article Influence: 661.5] [Reference Citation Analysis]
|
| 583 |
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 1323] [Article Influence: 661.5] [Reference Citation Analysis]
|
| 584 |
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 1323] [Article Influence: 661.5] [Reference Citation Analysis]
|
| 585 |
Liu Z, Liu L, Lu T, Wang L, Li Z, Jiao D, Han X. Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management.J Oncol. 2021;2021:6664386. [PMID: 33552157 DOI: 10.1155/2021/6664386] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 586 |
Xie XW, Jiang SS, Li X. CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma. Front Mol Biosci 2020;7:614034. [PMID: 33553242 DOI: 10.3389/fmolb.2020.614034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 587 |
Zhu P, Feng R, Lu X, Liao Y, Du Z, Zhai W, Chen K. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma. Aging (Albany NY) 2021;13:4138-56. [PMID: 33493134 DOI: 10.18632/aging.202380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 588 |
Fan Y, Yu Y, Hu M, Wang X, Du M, Guo L, Hu C. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma. Br J Radiol 2021;94:20200950. [PMID: 33417489 DOI: 10.1259/bjr.20200950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 589 |
Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 2021;11:3489-501. [PMID: 33537099 DOI: 10.7150/thno.54648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 590 |
Chen J, A Gingold J. Dysregulated PJA1-TGF-β signaling in cancer stem cell-associated liver cancers. Oncoscience 2020;7:88-95. [PMID: 33457451 DOI: 10.18632/oncoscience.522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 591 |
Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 592 |
Wu H, Wang MD, Liang L, Xing H, Zhang CW, Shen F, Huang DS, Yang T. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small 2021;17:e2005236. [PMID: 33448111 DOI: 10.1002/smll.202005236] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 593 |
Zhao H, Cheng X, Yu J, Li Y. Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells. Arch Biochem Biophys 2021;699:108754. [PMID: 33450239 DOI: 10.1016/j.abb.2021.108754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 594 |
Zhao F, Li C, Wu Y, Xia J, Zeng M, Li T, Xie K. Connective Tissue Growth Factor in Digestive System Cancers: A Review and Meta-Analysis. Biomed Res Int 2020;2020:8489093. [PMID: 33426067 DOI: 10.1155/2020/8489093] [Reference Citation Analysis]
|
| 595 |
Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma. Cells 2021;10:123. [PMID: 33440657 DOI: 10.3390/cells10010123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 596 |
Zhang N, Zhang S, Wu W, Lu W, Jiang M, Zheng N, Huang J, Wang L, Liu H, Zheng M, Wang J. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT. Mol Carcinog 2021;60:151-63. [PMID: 33428809 DOI: 10.1002/mc.23279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 597 |
Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 598 |
Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao D, Sun Z, Han X. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. J Transl Med 2021;19:5. [PMID: 33407585 DOI: 10.1186/s12967-020-02697-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 599 |
Min J, Jin D, Zhang F, Kang Y, Qi Y, Du P. DLG1-AS1 is activated by MYC and drives the proliferation and migration of hepatocellular carcinoma cells through miR-497-5p/SSRP1 axis. Cancer Cell Int 2021;21:16. [PMID: 33407499 DOI: 10.1186/s12935-020-01667-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 600 |
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers (Basel) 2021;13:E160. [PMID: 33466496 DOI: 10.3390/cancers13010160] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 601 |
Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 48.0] [Reference Citation Analysis]
|
| 602 |
Wang H, Calvisi DF, Chen X. Organoids for the Study of Liver Cancer. Semin Liver Dis 2021;41:19-27. [PMID: 33764482 DOI: 10.1055/s-0040-1719176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 603 |
Luo YD, Fang L, Yu HQ, Zhang J, Lin XT, Liu XY, Wu D, Li GX, Huang D, Zhang YJ, Chen S, Jiang Y, Shuai L, He Y, Zhang LD, Bie P, Xie CM. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. J Hepatol 2021;74:96-108. [PMID: 32738450 DOI: 10.1016/j.jhep.2020.07.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 604 |
Pocha PV, Xie C, Pocha C. Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. Ann Transl Med 2021;9:2. [PMID: 33553295 DOI: 10.21037/atm-20-7534] [Reference Citation Analysis]
|
| 605 |
Craig AJ, Wang XW. Molecular Carcinogenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_6] [Reference Citation Analysis]
|
| 606 |
Chen CL, Mo HQ, Jiang YH, Zhao XH, Ma S, You KY, Pan Y, Liu YM. BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma. J Cancer 2021;12:1507-19. [PMID: 33531996 DOI: 10.7150/jca.50293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 607 |
Weng H, Zeng L, Cao L, Chen T, Li Y, Xu Y, Peng Y, Ye Y. circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324. Mol Ther Nucleic Acids 2021;23:811-20. [PMID: 33614231 DOI: 10.1016/j.omtn.2020.12.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 608 |
Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatol Res 2021;51:5-18. [PMID: 32573056 DOI: 10.1111/hepr.13539] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 609 |
Shi X, Chen L, Chen S, Sun D. Electrochemical aptasensors for the detection of hepatocellular carcinoma-related biomarkers. New J Chem 2021;45:15158-69. [DOI: 10.1039/d1nj01042e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 610 |
Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. Int J Biol Sci 2021;17:220-35. [PMID: 33390845 DOI: 10.7150/ijbs.50730] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 611 |
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 134] [Cited by in F6Publishing: 146] [Article Influence: 67.0] [Reference Citation Analysis]
|
| 612 |
Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Front Immunol 2021;12:643310. [PMID: 33995362 DOI: 10.3389/fimmu.2021.643310] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 613 |
Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z, Zhou L. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg 2021;25:421-7. [PMID: 32026332 DOI: 10.1007/s11605-019-04492-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 614 |
Tan W, Lin Z, Chen X, Li W, Zhu S, Wei Y, Huo L, Chen Y, Shang C. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med 2021;9:38. [PMID: 33553331 DOI: 10.21037/atm-20-2081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 615 |
Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J. Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. J Cancer 2021;12:89-98. [PMID: 33391405 DOI: 10.7150/jca.47526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 616 |
Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical Treatments of Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:128-36. [PMID: 32438491 DOI: 10.1002/hep.31325] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 617 |
Lang TQ, Luo GY, Pu WC, Wang ZW, Wang J, Tian XL, Zhang P, Zhao NW, Yang WD, Chai HF. Three new 3-formyl-2-arylbenzofurans from Itea yunnanensis and their anti-hepatocellular carcinoma effects. Nat Prod Res 2020;:1-10. [PMID: 33375884 DOI: 10.1080/14786419.2020.1867130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 618 |
Liao LZ, Chen CT, Li NC, Lin LC, Huang BS, Chang YH, Chow LP. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci 2020;22:E224. [PMID: 33379356 DOI: 10.3390/ijms22010224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 619 |
Atwa SM, Handoussa H, Hosny KM, Odenthal M, El Tayebi HM. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. World J Hepatol 2020; 12(12): 1211-1227 [PMID: 33442449 DOI: 10.4254/wjh.v12.i12.1211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 620 |
Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin RA, Liang X, Cai X. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther 2020;5:298. [PMID: 33361760 DOI: 10.1038/s41392-020-00375-5] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 621 |
Dai T, Li L, Qi W, Liu B, Jiang Z, Song J, Hua H. Balanophorin B inhibited glycolysis with the involvement of HIF-1α. Life Sci 2021;267:118910. [PMID: 33359671 DOI: 10.1016/j.lfs.2020.118910] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 622 |
Fan D, Liu C, Li L, Lu C, Zhao N, Shu J, He X, Lu A. Deciphering Antitumor Mechanism of Pien Tze Huang in Mice of Hepatocellular Carcinoma Based on Proteomics. J Immunol Res 2020;2020:4876251. [PMID: 33344655 DOI: 10.1155/2020/4876251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 623 |
Huang DQ, Muthiah MD, Zhou L, Jumat H, Tan WX, Lee GH, Lim SG, Kow A, Bonney G, Shridhar I, Lim YT, Wee A, Pang YH, Soon G, Chow P, Dan YY. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cell Mol Gastroenterol Hepatol 2021;11:1313-25. [PMID: 33340714 DOI: 10.1016/j.jcmgh.2020.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 624 |
Xu G, Xue J, Jiang J, Liang T, Yao Y, Liao S, Chen T, Li H, Liu C, Zhan X. Proteomic analysis reveals critical molecular mechanisms involved in the macrophage anti-spinal tuberculosis process. Tuberculosis (Edinb) 2021;126:102039. [PMID: 33316736 DOI: 10.1016/j.tube.2020.102039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 625 |
Wang Q, Cheng B, Xue Q, Gao Q, Huang A, Wang K, Tang N. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.. [DOI: 10.1101/2020.12.14.422655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 626 |
Yang Y, Zheng J, Wang M, Zhang J, Tian T, Wang Z, Yuan S, Liu L, Zhu P, Gu F, Fu S, Shan Y, Pan Z, Zhou W. NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK-NRF2 signaling. Cancer Sci 2021;112:641-54. [PMID: 33222332 DOI: 10.1111/cas.14744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 627 |
Zhang J, Yang G, Li Q, Xie F. Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma. Oncol Lett 2021;21:92. [PMID: 33376525 DOI: 10.3892/ol.2020.12353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 628 |
Zhang EL, Zhang ZY, Li J, Huang ZY. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient. Onco Targets Ther 2020;13:12477-87. [PMID: 33311988 DOI: 10.2147/OTT.S284092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 629 |
Dhanaraj S, Shah T, O'rourke J, Shetty S. Hepatocellular carcinoma: update on treatment guidelines. Gastrointestinal Nursing 2020;18:S18-S26. [DOI: 10.12968/gasn.2020.18.sup10.s18] [Reference Citation Analysis]
|
| 630 |
Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1441-6. [PMID: 33119422 DOI: 10.1080/00365521.2020.1839127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 631 |
Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 632 |
Bezzecchi E, Ronzio M, Mantovani R, Dolfini D. NF-Y Overexpression in Liver Hepatocellular Carcinoma (HCC). Int J Mol Sci 2020;21:E9157. [PMID: 33271832 DOI: 10.3390/ijms21239157] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 633 |
Ahmed AE, Bayoumi E, Khayyal AE, Al Refaey AS, Elessawy H. Evaluation of diagnostic accuracy of serum calcium channel α2δ1 subunit in hepatocellular carcinoma-related cirrhosis. Egypt Liver Journal 2020;10:42. [DOI: 10.1186/s43066-020-00053-9] [Reference Citation Analysis]
|
| 634 |
Mantovani S, Varchetta S, Mele D, Donadon M, Torzilli G, Soldani C, Franceschini B, Porta C, Chiellino S, Pedrazzoli P, Santambrogio R, Barabino M, Cigala C, Piccolo G, Opocher E, Maestri M, Sangiovanni A, Bernuzzi S, Lhospice F, Kraiem M, Mondelli MU, Oliviero B. An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3583. [PMID: 33266137 DOI: 10.3390/cancers12123583] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 635 |
Liang C, Dong Z, Cai X, Shen J, Xu Y, Zhang M, Li H, Yu W, Chen W. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma. Cell Death Dis 2020;11:1017. [PMID: 33250518 DOI: 10.1038/s41419-020-03233-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 636 |
Wang H, Jiang Y, Li B, Cui Y, Li D, Li R. Single-Cell Spatial Analysis of Tumor and Immune Microenvironment on Whole-Slide Image Reveals Hepatocellular Carcinoma Subtypes. Cancers (Basel) 2020;12:E3562. [PMID: 33260561 DOI: 10.3390/cancers12123562] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 637 |
Liu P, Tang Q, Chen M, Chen W, Lu Y, Liu Z, He Z. Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma. Front Oncol 2020;10:589908. [PMID: 33330071 DOI: 10.3389/fonc.2020.589908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 638 |
Wang M, Huang S, Chen Z, Han Z, Li K, Chen C, Wu G, Zhao Y. Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer 2020;20:1136. [PMID: 33228611 DOI: 10.1186/s12885-020-07625-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 639 |
Zhao Z, Zhang D, Wu F, Tu J, Song J, Xu M, Ji J. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med 2021;25:549-60. [PMID: 33210432 DOI: 10.1111/jcmm.16108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 640 |
Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma. Aging (Albany NY) 2020;12:22975-3003. [PMID: 33203790 DOI: 10.18632/aging.104028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 641 |
Zhang K, Zhang M, Luo Z, Wen Z, Yan X. The dichotomous role of TGF-β in controlling liver cancer cell survival and proliferation. J Genet Genomics 2020;47:497-512. [PMID: 33339765 DOI: 10.1016/j.jgg.2020.09.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 642 |
Serra M, Columbano A, Perra A, Kowalik MA. Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3318. [PMID: 33182674 DOI: 10.3390/cancers12113318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 643 |
Hu B, Yang XB, Sang XT. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. Int Immunopharmacol 2021;90:107164. [PMID: 33172741 DOI: 10.1016/j.intimp.2020.107164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 644 |
Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 645 |
Zou W, Hu X, Jiang L. Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling. Curr Cancer Drug Targets 2020;20:779-88. [PMID: 32748747 DOI: 10.2174/1568009620999200730183631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 646 |
Zhang GC, Liu J, Yu XN, Deng Y, Sun Y, Liu TT, Dong L, Zhu CF, Shen XZ, Zhu JM, Weng SQ, Li Y. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. Adv Healthc Mater 2020;9:e2000650. [PMID: 33000919 DOI: 10.1002/adhm.202000650] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 647 |
Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1017-24. [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 648 |
Tsang ES, Davies JM, Loree JM, Lim HJ, Renouf DJ, Gill S. Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology 2020;43:788-791. [DOI: 10.1097/coc.0000000000000754] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 649 |
Vyas M, Zhang X. Hepatocellular Carcinoma: Role of Pathology in the Era of Precision Medicine. Clin Liver Dis 2020;24:591-610. [PMID: 33012447 DOI: 10.1016/j.cld.2020.07.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 650 |
Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. Eur Radiol 2021;31:2737-46. [PMID: 33123796 DOI: 10.1007/s00330-020-07381-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 651 |
Hou T, Wang T, Mu W, Yang R, Liang S, Zhang Z, Fu S, Gao T, Liu Y, Zhang N. Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy. Nanomicro Lett 2020;13:6. [PMID: 34138195 DOI: 10.1007/s40820-020-00531-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 652 |
Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 2020;11:902. [PMID: 33097691 DOI: 10.1038/s41419-020-03123-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 653 |
Dalwadi DA, Torrens L, Abril-Fornaguera J, Pinyol R, Willoughby C, Posey J, Llovet JM, Lanciault C, Russell DW, Grompe M, Naugler WE. Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Mol Ther 2021;29:680-90. [PMID: 33554867 DOI: 10.1016/j.ymthe.2020.10.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 654 |
Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 655 |
Ahmed S, Gordon L, Dueck DA, Souied O, Haider K. Current status of systemic therapy in hepatocellular cancer. Dig Liver Dis 2020:S1590-8658(20)30933-6. [PMID: 34756361 DOI: 10.1016/j.dld.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 656 |
Dai Y, Qiang W, Lin K, Gui Y, Lan X, Wang D. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:967-79. [PMID: 33089373 DOI: 10.1007/s00262-020-02743-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 48] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 657 |
Dong X, Feng M, Yang H, Liu H, Guo H, Gao X, Liu Y, Liu R, Zhang N, Chen R, Kong R. Rictor promotes cell migration and actin polymerization through regulating ABLIM1 phosphorylation in Hepatocellular Carcinoma. Int J Biol Sci 2020;16:2835-52. [PMID: 33061800 DOI: 10.7150/ijbs.46285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 658 |
Zhou J, Zhou Q, Shu G, Wang X, Lu Y, Chen H, Hu T, Cai J, Du Y, Yu R. Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2020;15:7235-49. [PMID: 33061378 DOI: 10.2147/IJN.S257628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 659 |
Sheng LQ, Li JR, Qin H, Liu L, Zhang DD, Zhang Q, Huang ML, Li XL, Xu XY, Wei YN, Chen ZS, Luo H, Zhang JY, Zhou CH, Chen H, Chen ZG, Li FG, Li NF. Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis. World J Gastrointest Oncol 2020; 12(10): 1195-1208 [PMID: 33133386 DOI: 10.4251/wjgo.v12.i10.1195] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 660 |
Wang Y, Jiang M, Zhu J, Qu J, Qin K, Zhao D, Wang L, Dong L, Zhang X. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother 2020;132:110797. [PMID: 33068935 DOI: 10.1016/j.biopha.2020.110797] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 661 |
Li L, Shen L, Ma J, Zhou Q, Li M, Wu H, Wei M, Zhang D, Wang T, Qin S, Xing T. Evaluating Distribution and Prognostic Value of New Tumor-Infiltrating Lymphocytes in HCC Based on a scRNA-Seq Study With CIBERSORTx. Front Med (Lausanne) 2020;7:451. [PMID: 33043022 DOI: 10.3389/fmed.2020.00451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 662 |
Zhao Z, Gao J, Li C, Xu X, Hu Y, Huang S. Reactive Oxygen Species Induce Endothelial Differentiation of Liver Cancer Stem-Like Sphere Cells through the Activation of Akt/IKK Signaling Pathway. Oxid Med Cell Longev 2020;2020:1621687. [PMID: 33101583 DOI: 10.1155/2020/1621687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 663 |
Woodrell CD, Goldstein NE, Moreno JR, Schiano TD, Schwartz ME, Garrido MM. Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. J Pain Symptom Manage 2021;61:940-947.e3. [PMID: 33035651 DOI: 10.1016/j.jpainsymman.2020.09.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 664 |
Vale N, Duarte D, Silva S, Correia AS, Costa B, Gouveia MJ, Ferreira A. Cell-penetrating peptides in oncologic pharmacotherapy: A review. Pharmacol Res 2020;162:105231. [PMID: 33027717 DOI: 10.1016/j.phrs.2020.105231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 665 |
Nishida N, Sakai K, Morita M, Aoki T, Takita M, Hagiwara S, Komeda Y, Takenaka M, Minami Y, Ida H, Ueshima K, Nishio K, Kudo M. Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. Liver Cancer 2020;9:426-39. [PMID: 32999869 DOI: 10.1159/000506352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 666 |
Li J, Zhou J, Kai S, Wang C, Wang D, Jiang J. Functional and Clinical Characterization of Tumor-Infiltrating T Cell Subpopulations in Hepatocellular Carcinoma. Front Genet 2020;11:586415. [PMID: 33133170 DOI: 10.3389/fgene.2020.586415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 667 |
Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 668 |
Zhao W, Bai B, Hong Z, Zhang X, Zhou B. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells. ACS Omega 2020;5:24838-47. [PMID: 33015502 DOI: 10.1021/acsomega.0c03527] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 669 |
Hu X, Bao M, Huang J, Zhou L, Zheng S. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 2020;10:541479. [PMID: 33102213 DOI: 10.3389/fonc.2020.541479] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 670 |
Frizziero M, McNamara MG, Lamarca A, Pihlak R, Kurup R, Hubner RA. Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. Curr Med Chem 2020;27:4789-805. [PMID: 32321391 DOI: 10.2174/0929867327666200422143847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 671 |
Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 672 |
Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020;111:4218-4231. [PMID: 32889778 DOI: 10.1111/cas.14641] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 673 |
Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 674 |
Li R, Gong J, Xiao C, Zhu S, Hu Z, Liang J, Li X, Yan X, Zhang X, Li D, Liu W, Chong Y, Jie Y. A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma. Genomics. 2020;112:5101-5114. [PMID: 32941982 DOI: 10.1016/j.ygeno.2020.09.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 675 |
de Conti A, Tryndyak V, Heidor R, Jimenez L, Moreno FS, Beland FA, Rusyn I, Pogribny IP. Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis. J Nutr Biochem 2020;86:108496. [PMID: 32920087 DOI: 10.1016/j.jnutbio.2020.108496] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 676 |
Rawat D, Chhonker SK, Naik RA, Koiri RK. Modulation of antioxidant enzymes, SIRT1 and NF-κB by resveratrol and nicotinamide in alcohol-aflatoxin B1-induced hepatocellular carcinoma. J Biochem Mol Toxicol 2021;35:e22625. [PMID: 32894639 DOI: 10.1002/jbt.22625] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 677 |
Cai Y, Zheng Q, Yao DJ. Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 is a diagnostic and prognostic biomarker for hepatocellular carcinoma. World J Clin Cases 2020; 8(17): 3774-3785 [PMID: 32953853 DOI: 10.12998/wjcc.v8.i17.3774] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 678 |
Chen DB, Xie XW, Zhao YJ, Wang XY, Liao WJ, Chen P, Deng KJ, Fei R, Qin WY, Wang JH, Wu X, Shao QX, Wei L, Chen HS. RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A. Sci Rep 2020;10:14538. [PMID: 32883983 DOI: 10.1038/s41598-020-71403-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 679 |
Heinrich S, Castven D, Galle PR, Marquardt JU. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2495. [PMID: 32899197 DOI: 10.3390/cancers12092495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 680 |
Enomoto H, Nakamura H, Nishikawa H, Nishimura T, Iwata Y, Nishiguchi S, Iijima H. Hepatocellular Carcinoma-associated microRNAs Induced by Hepatoma-derived Growth Factor Stimulation. In Vivo 2020;34:2297-301. [PMID: 32871753 DOI: 10.21873/invivo.12041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 681 |
Frizziero M, Mcnamara MG, Lamarca A, Pihlak R, Kurup R, Hubner RA. Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. CMC 2020;27:4789-805. [DOI: 10.2174/0929867327666200422143847] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 682 |
Huang M, Zhao Q, Ye Z, Xu D, Tang S, Jiang T. Development of a novel melatonin-modified near-infrared fluorescent probe for in vivo hepatocellular carcinoma imaging. Anal Methods 2020;12:4556-61. [PMID: 33001063 DOI: 10.1039/d0ay01135e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 683 |
Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, Franch-Expósito S, Vila-Casadesús M, Salaverria I, Montal R, Mazzaferro V, Camps J, Sia D, Llovet JM. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clin Cancer Res 2020;26:6350-61. [PMID: 32873569 DOI: 10.1158/1078-0432.CCR-20-1497] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 684 |
Paur J, Valler M, Sienel R, Taxauer K, Holzmann K, Marian B, Unterberger A, Mohr T, Berger W, Gvozdenovich A, Schimming J, Grusch M, Grasl-Kraupp B. Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma. Liver Int 2020;40:2279-90. [PMID: 32378800 DOI: 10.1111/liv.14505] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 685 |
Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 686 |
Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 2020;9:613-24. [PMID: 33083284 DOI: 10.1159/000508901] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 687 |
Hwangbo H, Kim SY, Lee H, Park SH, Hong SH, Park C, Kim GY, Leem SH, Hyun JW, Cheong J, Choi YH. Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway. Biomol Ther (Seoul) 2020;28:443-55. [PMID: 32856616 DOI: 10.4062/biomolther.2020.122] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 688 |
Dai Y, Han B, Dong L, Zhao J, Cao Y. Recent advances in nanomaterial-enhanced biosensing methods for hepatocellular carcinoma diagnosis. TrAC Trends in Analytical Chemistry 2020;130:115965. [DOI: 10.1016/j.trac.2020.115965] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 689 |
Uchida S, Kauppinen S. Long Non-Coding RNAs in Liver Cancer and Nonalcoholic Steatohepatitis. Noncoding RNA 2020;6:E34. [PMID: 32872482 DOI: 10.3390/ncrna6030034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 690 |
Li Y, Chen R, Yang J, Mo S, Quek K, Kok CH, Cheng XD, Tian S, Zhang W, Qin JJ. Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. Front Genet 2020;11:814. [PMID: 32849813 DOI: 10.3389/fgene.2020.00814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 691 |
Xiao H, Wang B, Xiong HX, Guan JF, Wang J, Tan T, Lin K, Zou SB, Hu ZG, Wang K. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. J Cell Physiol 2021;236:2572-91. [PMID: 32853412 DOI: 10.1002/jcp.30015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 692 |
Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 693 |
Liu C, Miao X, Wang Y, Wen L, Cheng X, Kong D, Zhao P, Song D, Wang X, Ding X, Xia H, Wang W, Sun Q, Gong W. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. Cancer Sci 2020;111:3503-15. [PMID: 32726482 DOI: 10.1111/cas.14588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 694 |
Xiao Q, Liu H, Wang HS, Cao MT, Meng XJ, Xiang YL, Zhang YQ, Shu F, Zhang QG, Shan H, Jiang GM. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy. Theranostics 2020;10:10245-61. [PMID: 32929346 DOI: 10.7150/thno.47045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 695 |
Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem 2020;27:3290-301. [PMID: 31232234 DOI: 10.2174/0929867326666190624161158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 696 |
Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Rep 2020;2:100167. [PMID: 33134907 DOI: 10.1016/j.jhepr.2020.100167] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 697 |
Hu Z, Xin H, Luo C, Li J, Zhou Z, Zou J, Zhou S. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:377-89. [DOI: 10.1007/s00262-020-02685-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 698 |
Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 699 |
Liu X, Niu X, Qiu Z. A Five-Gene Signature Based on Stromal/Immune Scores in the Tumor Microenvironment and Its Clinical Implications for Liver Cancer. DNA Cell Biol 2020;39:1621-38. [PMID: 32758021 DOI: 10.1089/dna.2020.5512] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 700 |
Golkowski M, Lau HT, Chan M, Kenerson H, Vidadala VN, Shoemaker A, Maly DJ, Yeung RS, Gujral TS, Ong SE. Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Syst 2020;11:196-207.e7. [PMID: 32755597 DOI: 10.1016/j.cels.2020.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 701 |
Lee MJ, Chang SW, Kim JH, Lee YS, Cho SB, Seo YS, Yim HJ, Hwang SY, Lee HW, Chang Y, Jang JY. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Invest New Drugs 2021;39:260-8. [PMID: 32749658 DOI: 10.1007/s10637-020-00977-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 702 |
Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 703 |
Lv X, Yu H, Zhang Q, Huang Q, Hong X, Yu T, Lan H, Mei C, Zhang W, Luo H, Pang P, Shan H. SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. J Cell Mol Med 2020;24:10714-29. [PMID: 32746503 DOI: 10.1111/jcmm.15693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 704 |
Nishida N, Sakai K, Morita M, Aoki T, Takita M, Hagiwara S, Komeda Y, Takenaka M, Minami Y, Ida H, Ueshima K, Nishio K, Kudo M. Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. Liver Cancer 2020;9:426-39. [PMID: 32999869 DOI: 10.1159/000506352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 705 |
Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 118] [Cited by in F6Publishing: 132] [Article Influence: 39.3] [Reference Citation Analysis]
|
| 706 |
Zhang YP, Bao ZW, Wu JB, Chen YH, Chen JR, Xie HY, Zhou L, Wu J, Zheng SS. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy. Technol Cancer Res Treat 2020;19:1533033820944274. [PMID: 32715976 DOI: 10.1177/1533033820944274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 707 |
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 338] [Cited by in F6Publishing: 391] [Article Influence: 112.7] [Reference Citation Analysis]
|
| 708 |
Lu Y, Fang Z, Li M, Chen Q, Zeng T, Lu L, Chen Q, Zhang H, Zhou Q, Sun Y, Xue X, Hu Y, Chen L, Su S. Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing. J Mol Cell Biol 2019;11:665-77. [PMID: 30925583 DOI: 10.1093/jmcb/mjz025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 709 |
Li J, Xia T, Cao J, He D, Chen Z, Liang B, Song J. RP11-295G20.2 facilitates hepatocellular carcinoma progression via the miR-6884-3p/CCNB1 pathway. Aging (Albany NY) 2020;12:14918-32. [PMID: 32687483 DOI: 10.18632/aging.103552] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 710 |
Li B, Yao J, Guo K, He F, Chen K, Lin Z, Liu S, Huang J, Wu Q, Fang M, Zeng J, Wu Z. Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators. Eur J Med Chem 2020;204:112608. [PMID: 32717483 DOI: 10.1016/j.ejmech.2020.112608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 711 |
Zhang Q, Lou Y, Bai XL, Liang TB. Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World J Gastroenterol 2020; 26(26): 3720-3736 [PMID: 32774053 DOI: 10.3748/wjg.v26.i26.3720] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 712 |
Zhang Q, Liao J, Qiao L, Liu Q, Liu P, Xia M, Huang X, Liu L. A novel hypoxia gene signature indicates prognosis and reveals the multi-omics molecular landscape of tumour tissue in patients with hepatocellular carcinoma.. [DOI: 10.1101/2020.07.10.198176] [Reference Citation Analysis]
|
| 713 |
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers (Basel) 2020;12:E1867. [PMID: 32664489 DOI: 10.3390/cancers12071867] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 714 |
Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 715 |
Huaman J, Ogunwobi OO. Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. Cells 2020;9:E1594. [PMID: 32630254 DOI: 10.3390/cells9071594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 716 |
Zhuo JY, Lu D, Tan WY, Zheng SS, Shen YQ, Xu X. CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype. J Cancer 2020;11:5069-77. [PMID: 32742454 DOI: 10.7150/jca.44697] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 717 |
Simsek C, Kim A, Ma M, Danis N, Gurakar M, Cameron AM, Philosophe B, Garonzik-Wang J, Ottmann S, Gurakar A, Saberi B. Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series. Hepatoma Res 2020;6:11. [PMID: 32582866 DOI: 10.20517/2394-5079.2019.51] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 718 |
Ohshiro K, Chen J, Srivastav J, Mishra L, Mishra B. Alterations in TGF-β signaling leads to high HMGA2 levels potentially through modulation of PJA1/SMAD3 in HCC cells. Genes Cancer 2020;11:43-52. [PMID: 32577156 DOI: 10.18632/genesandcancer.199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 719 |
Liu Z, Lin Y, Gao X, Mai R, Piao X, Ye J, Liang R. Construction of a Comprehensive Multiomics Map of Hepatocellular Carcinoma and Screening of Possible Driver Genes. Front Genet 2020;11:634. [PMID: 32670354 DOI: 10.3389/fgene.2020.00634] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 720 |
Zhang Q, Cheng Q, Xia M, Huang X, He X, Liao J. Hypoxia-Induced lncRNA-NEAT1 Sustains the Growth of Hepatocellular Carcinoma via Regulation of miR-199a-3p/UCK2. Front Oncol 2020;10:998. [PMID: 32670881 DOI: 10.3389/fonc.2020.00998] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 721 |
Kwok A, Raulf N, Habib N. Developing small activating RNA as a therapeutic: current challenges and promises. Ther Deliv 2019;10:151-64. [PMID: 30909853 DOI: 10.4155/tde-2018-0061] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 722 |
Wang D, Yang X, Lin J, Bai Y, Long J, Yang X, Seery S, Zhao H. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therap Adv Gastroenterol 2020;13:1756284820932483. [PMID: 32636928 DOI: 10.1177/1756284820932483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 723 |
Tian M, Yang X, Li Y, Guo S. The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis. Med Sci Monit 2020;26:e923359. [PMID: 32573516 DOI: 10.12659/MSM.923359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 724 |
Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 725 |
Hu G, Yan C, Xie P, Cao Y, Shao J, Ge J. PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation. Exp Cell Res 2020;394:112152. [PMID: 32574605 DOI: 10.1016/j.yexcr.2020.112152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 726 |
Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 2020;20:2257-65. [PMID: 32782543 DOI: 10.3892/ol.2020.11758] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 727 |
Zhao J, Wu J, He M, Cao M, Lei J, Luo H, Yi F, Ding J, Wei Y, Zhang W. Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis. Int J Hyperthermia 2020;37:624-33. [PMID: 32525724 DOI: 10.1080/02656736.2020.1774667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 728 |
Jin M, Shi C, Li T, Wu Y, Hu C, Huang G. Solasonine promotes ferroptosis of hepatoma carcinoma cells via glutathione peroxidase 4-induced destruction of the glutathione redox system. Biomed Pharmacother 2020;129:110282. [PMID: 32531676 DOI: 10.1016/j.biopha.2020.110282] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 729 |
Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346] [Reference Citation Analysis]
|
| 730 |
Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 731 |
Agioutantis PC, Loutrari H, Kolisis FN. Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines. Genes (Basel) 2020;11:E623. [PMID: 32517019 DOI: 10.3390/genes11060623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 732 |
Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genomics Proteomics 2020;17:1-21. [PMID: 31882547 DOI: 10.21873/cgp.20163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 733 |
von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 734 |
Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 73] [Cited by in F6Publishing: 89] [Article Influence: 24.3] [Reference Citation Analysis]
|
| 735 |
Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 29.7] [Reference Citation Analysis]
|
| 736 |
Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 737 |
Jones SF, McKenzie AJ. Molecular Profiling in Drug Development: Paving a Way Forward. Am Soc Clin Oncol Educ Book 2020;40:309-18. [PMID: 32463698 DOI: 10.1200/EDBK_100024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 738 |
Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 739 |
Chen J, Rong X, Liu X, Zheng D, Rong X, Chen F, Zhao P, Liu F, Ruan J. FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma. Cancer Cell Int 2020;20:196. [PMID: 32508532 DOI: 10.1186/s12935-020-01265-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 740 |
Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 741 |
Ma A, Zhang R. Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer. Cancer Manag Res 2020;12:3537-46. [PMID: 32547191 DOI: 10.2147/CMAR.S240064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 742 |
Wang M, Yu F, Chen X, Li P, Wang K. The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2020;21:13-27. [PMID: 32505000 DOI: 10.1016/j.omtn.2020.05.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 743 |
Qiu LW, Liu YF, Cao XQ, Wang Y, Cui XH, Ye X, Huang SW, Xie HJ, Zhang HJ. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World J Gastroenterol 2020; 26(18): 2126-2137 [PMID: 32476780 DOI: 10.3748/wjg.v26.i18.2126] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 744 |
Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 745 |
von Felden J. New systemic agents for hepatocellular carcinoma: an update 2020. Curr Opin Gastroenterol 2020;36:177-83. [PMID: 32101985 DOI: 10.1097/MOG.0000000000000626] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 746 |
Hack SP, Spahn J, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology 2020;16:975-89. [DOI: 10.2217/fon-2020-0162] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 19.7] [Reference Citation Analysis]
|
| 747 |
Guo Q, Yu DY, Yang ZF, Liu DY, Cao HQ, Liao XW. IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway. Dig Liver Dis 2020;52:573-81. [PMID: 31818638 DOI: 10.1016/j.dld.2019.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 748 |
Ma XL, Tang WG, Yang MJ, Xie SH, Wu ML, Lin G, Lu RQ. Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma. Front Oncol 2020;10:511. [PMID: 32426271 DOI: 10.3389/fonc.2020.00511] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 749 |
Yang S, Wang M, Yang L, Li Y, Ma Y, Peng X, Li X, Li B, Jin H, Li H. MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib. Onco Targets Ther 2020;13:3557-70. [PMID: 32431510 DOI: 10.2147/OTT.S247655] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 750 |
Zhang Y, Zhang L, Xu Y, Wu X, Zhou Y, Mo J. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol 2020;235:9304-16. [PMID: 32330311 DOI: 10.1002/jcp.29730] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 751 |
Luo YD, Yu HQ, Liu XY, Huang D, Dai HS, Fang L, Zhang YJ, Lai JJ, Jiang Y, Shuai L, Zhang LD, Chen G, Bie P, Xie CM. Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma. Cancer Med 2020;9:4083-94. [PMID: 32293796 DOI: 10.1002/cam4.3040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 752 |
Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020;19:77. [PMID: 32295598 DOI: 10.1186/s12943-020-01188-4] [Cited by in Crossref: 201] [Cited by in F6Publishing: 209] [Article Influence: 67.0] [Reference Citation Analysis]
|
| 753 |
Chen H, Cheng H, Dai Q, Cheng Y, Zhang Y, Li D, Sun Y, Mao J, Ren K, Chu C, Liu G. A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment.J Control Release. 2020;323:635-643. [PMID: 32302761 DOI: 10.1016/j.jconrel.2020.04.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 754 |
Lin P, Wen DY, Chen G, Dang YW, He Y, Yang H. Predictive value of hypoxia, metabolism and immune factors for prognosis in hepatocellular carcinoma: a retrospective analysis and multicenter validation study. J Cancer 2020;11:4145-56. [PMID: 32368297 DOI: 10.7150/jca.41983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 755 |
Gao J, Zhang HP, Sun YH, Guo WZ, Li J, Tang HW, Guo DF, Zhang JK, Shi XY, Yu DS, Zhang XD, Wen PH, Shi JH, Zhang SJ. Synaptopodin-2 promotes hepatocellular carcinoma metastasis via calcineurin-induced nuclear-cytoplasmic translocation. Cancer Lett 2020;482:8-18. [PMID: 32278815 DOI: 10.1016/j.canlet.2020.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 756 |
Ma X, Zhou L, Zheng S. Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma. PeerJ 2020;8:e8930. [PMID: 32296612 DOI: 10.7717/peerj.8930] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 757 |
Yao S, Ye J, Yin M, Yu R. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Lett 2020;483:87-97. [PMID: 32268165 DOI: 10.1016/j.canlet.2020.04.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 758 |
Zhang C, Sheng L, Yuan M, Hu J, Meng Y, Wu Y, Chen L, Yu H, Li S, Zheng G, Qiu Z. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met. Toxicology and Applied Pharmacology 2020;392:114918. [DOI: 10.1016/j.taap.2020.114918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 759 |
Zarrinpar A, Kim UB, Boominathan V. Phenotypic Response and Personalized Medicine in Liver Cancer and Transplantation: Approaches to Complex Systems. Adv Therap 2020;3:1900167. [DOI: 10.1002/adtp.201900167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 760 |
Park J, Cho J, Lim JH, Lee MH, Kim J. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis. Target Oncol. 2019;14:395-403. [PMID: 31290003 DOI: 10.1007/s11523-019-00651-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 761 |
Shu W, Wang Y, Liu C, Li R, Pei C, Lou W, Lin S, Di W, Wan J. Construction of a Plasmonic Chip for Metabolic Analysis in Cervical Cancer Screening and Evaluation. Small Methods 2020;4:1900469. [DOI: 10.1002/smtd.201900469] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 762 |
Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp Med 2020;20:329-37. [PMID: 32239299 DOI: 10.1007/s10238-020-00620-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 763 |
Tan AT, Schreiber S. Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research 2020;176:104748. [DOI: 10.1016/j.antiviral.2020.104748] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 764 |
Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 17.3] [Reference Citation Analysis]
|
| 765 |
Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 766 |
Zhao X, Qin W, Jiang Y, Yang Z, Yuan B, Dai R, Shen H, Chen Y, Fu J, Wang H. ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma. NPJ Precis Oncol 2020;4:7. [PMID: 32219176 DOI: 10.1038/s41698-020-0111-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 767 |
Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP18. [PMID: 32273976 DOI: 10.2217/hep-2020-0001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 768 |
Mei J, Wang H, Wang R, Pan J, Liu C, Xu J. Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:5751939. [PMID: 32258128 DOI: 10.1155/2020/5751939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 769 |
Schulte LA, López-Gil JC, Sainz B Jr, Hermann PC. The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E684. [PMID: 32183251 DOI: 10.3390/cancers12030684] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 770 |
Perrin-cocon L, Vidalain P, Jacquemin C, Aublin-gex A, Olmstead K, Panthu B, Rautureau GJP, André P, Nyczka P, Hütt M, Amoedo N, Rossignol R, Filipp FV, Lotteau V, Diaz O. Lipogenesis and innate immunity in hepatocellular carcinoma cells reprogrammed by an isoenzyme switch of hexokinases.. [DOI: 10.1101/2020.03.13.973321] [Reference Citation Analysis]
|
| 771 |
Wu XM, Jin C, Gu YL, Chen WQ, Zhu MQ, Zhang S, Zhang Z. Gluconokinase IDNK Promotes Cell Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:1767-76. [PMID: 32161472 DOI: 10.2147/OTT.S234055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 772 |
Dufour J. Le carcinome hépatocellulaire. Schweiz Gastroenterol 2020;1:18-22. [DOI: 10.1007/s43472-020-00005-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 773 |
Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Asahina Y, Hayashi T, Terashima T, Iida N, Takatori H, Shimakami T, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Takamura H, Ohta T, Honda M, Kaneko S. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2020;10:269-85. [PMID: 32169577 DOI: 10.1016/j.jcmgh.2020.02.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 774 |
Chen J, Mitra A, Li S, Song S, Nguyen BN, Chen JS, Shin JH, Gough NR, Lin P, Obias V, He AR, Yao Z, Malta TM, Noushmehr H, Latham PS, Su X, Rashid A, Mishra B, Wu RC, Mishra L. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling. Cancer Res 2020;80:1819-32. [PMID: 32127355 DOI: 10.1158/0008-5472.CAN-19-3116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 775 |
Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JH, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proc Natl Acad Sci U S A 2020;117:6103-13. [PMID: 32123069 DOI: 10.1073/pnas.1912146117] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 776 |
Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, Fujishiro M. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 2020;50:374-81. [PMID: 31721363 DOI: 10.1111/hepr.13452] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 777 |
Zhao X, Su X, Cao L, Xie T, Chen Q, Li J, Xu R, Jiang C. OTUD4: A Potential Prognosis Biomarker for Multiple Human Cancers. Cancer Manag Res 2020;12:1503-12. [PMID: 32184655 DOI: 10.2147/CMAR.S233028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 778 |
Lordick F. Hepatocellular carcinoma-united forces against a global killer. Ann Oncol 2020;31:449-50. [PMID: 32122696 DOI: 10.1016/j.annonc.2020.01.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 779 |
Raoul JL, Edeline J. Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncol 2020;21:479-81. [PMID: 32112736 DOI: 10.1016/S1470-2045(20)30082-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 780 |
Tang L, Chen R, Xu X. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. Cancer Lett 2020;476:120-8. [PMID: 32070778 DOI: 10.1016/j.canlet.2020.02.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 781 |
Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs 2020;80:315-22. [DOI: 10.1007/s40265-020-01263-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 782 |
Li Z, Li H, Deng D, Liu R, Lv Y. Mass Spectrometric Assay of Alpha-Fetoprotein Isoforms for Accurate Serological Evaluation. Anal Chem 2020;92:4807-13. [DOI: 10.1021/acs.analchem.9b03995] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 783 |
Luo LH, Jin M, Wang LQ, Xu GJ, Lin ZY, Yu DD, Yang SL, Ran RZ, Wu G, Zhang T. Long noncoding RNA TCL6 binds to miR-106a-5p to regulate hepatocellular carcinoma cells through PI3K/AKT signaling pathway. J Cell Physiol. 2020;235:6154-6166. [PMID: 32020591 DOI: 10.1002/jcp.29544] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 784 |
Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 785 |
Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2020;38:1081. [PMID: 32013670 DOI: 10.1200/JCO.19.03141] [Cited by in Crossref: 60] [Cited by in F6Publishing: 69] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 786 |
Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 787 |
Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol 2020;72:342-52. [PMID: 31954496 DOI: 10.1016/j.jhep.2019.09.010] [Cited by in Crossref: 188] [Cited by in F6Publishing: 195] [Article Influence: 62.7] [Reference Citation Analysis]
|
| 788 |
Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 162] [Cited by in F6Publishing: 171] [Article Influence: 54.0] [Reference Citation Analysis]
|
| 789 |
Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol 2020;72:239-49. [PMID: 31954489 DOI: 10.1016/j.jhep.2019.09.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 790 |
Shen J, Chen M, Lee D, Law CT, Wei L, Tsang FH, Chin DW, Cheng CL, Lee JM, Ng IO, Wong CC, Wong CM. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. Gut 2020;69:329-42. [PMID: 31439637 DOI: 10.1136/gutjnl-2019-318668] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 791 |
Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol 2020;72:262-76. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 792 |
Chen J, Duda DG. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. EBioMedicine 2020;52:102644. [PMID: 32014823 DOI: 10.1016/j.ebiom.2020.102644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 793 |
Casadei-Gardini A, Del Coco L, Marisi G, Conti F, Rovesti G, Ulivi P, Canale M, Frassineti GL, Foschi FG, Longo S, Fanizzi FP, Giudetti AM. 1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. Cancers (Basel) 2020;12:E241. [PMID: 31963766 DOI: 10.3390/cancers12010241] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 794 |
Lin J, Zhao H. Systemic management for patients with hepatobiliary tumors in a multi-dimensional view. Hepatobiliary Surg Nutr 2019;8:626-8. [PMID: 31929990 DOI: 10.21037/hbsn.2019.07.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 795 |
Yang PM, Lin LS, Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020;10:E117. [PMID: 31936661 DOI: 10.3390/biom10010117] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 796 |
Pan X, Lin P, Feng F, Li J, Li Y, Dai W, Hu B, Yang X, Fan J, Li H, Li Y. Comparison of immune profiles between hepatocellular carcinoma subtypes. Biophys Rep 2020;6:19-32. [DOI: 10.1007/s41048-019-00102-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 797 |
Jin W. Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer. Cancers (Basel) 2020;12:E147. [PMID: 31936239 DOI: 10.3390/cancers12010147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 798 |
Raoul JL, Faivre S, Frenel JS, Rimassa L. Medical oncologists must get more involved in systemic treatment. Ann Oncol 2019;30:6-8. [PMID: 32081277 DOI: 10.1093/annonc/mdy471] |
